Flow cell and method

By using flow cell technology to tag and amplify DNA samples under the action of surface chemicals, the problems of low efficiency and long time consumption of existing methods are solved, and efficient DNA library construction and sample indexing are achieved.

CN118974273APending Publication Date: 2024-11-15ILLUMINA INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380031322.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-21
Filing Date
2023-12-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing methods for fragmenting and labeling double-stranded DNA (dsDNA) target molecules are inefficient and time-consuming, especially involving expensive equipment and generating excessive waste.

Method used

By employing flow cell technology, surface chemicals are used for tag fragmentation and amplification. Transposable complexes are activated in predetermined regions of the flow cell through photoactivation, thermal or pH changes, enabling selective and sequential sample introduction and cluster generation, improving efficiency and enabling spatial indexing.

Benefits of technology

It improves the efficiency of DNA sample fragmentation and amplification, reduces reliance on expensive instruments, simplifies the DNA sample preparation process, and enables more efficient DNA library construction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974273A_ABST
    Figure CN118974273A_ABST
Patent Text Reader

Abstract

One example of a flow cell includes: a substrate having recesses separated by interstitial regions; a polymeric hydrogel positioned within each of the recesses; and a plurality of transposon complexes secured within each of the recesses by a biotin-containing linker. In this example, each of the plurality of transposon complexes is of a single type, including a transposon terminal, where a portion of a transfer strand hybridizes to a portion of a non-transfer strand, where the transfer strand includes a first amplification domain and does not include an index sequence.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 601,655 filed on November 21, 2023 and U.S. Provisional Patent Application Serial No. 63 / 586,716 filed on September 29, 2023, as well as U.S. Provisional Patent Application Serial No. 63 / 476,585 filed on December 21, 2022 and U.S. Provisional Patent Application Serial No. 63 / 387,874 filed on December 16, 2022, the contents of each of which are incorporated herein by reference in their entirety.

[0003] References to sequence listings

[0004] The sequence listing submitted herewith is hereby incorporated by reference in its entirety. The name of the file is ILI256BPCT_IP-2542-PCT_Sequence_Listing.xml, the size of the file is 14,888 bytes, and the creation date of the file is December 14, 2023. Background Art

[0005] Double-stranded DNA (dsDNA) target molecules can be fragmented and labeled to produce smaller single-stranded DNA molecules (ssDNA) libraries. These smaller single-stranded DNA molecules can be used as templates in DNA sequencing reactions. The template can enable short read lengths to be obtained, and then during data analysis, overlapping short sequence reads can be compared to reconstruct longer nucleotide sequences. Some methods for fragmentation and labeling of double-stranded DNA produce too much waste, involve expensive instruments for fragmentation, and are time-consuming. Summary of the invention

[0006] Some examples of flow cells disclosed herein include surface chemistries that enable reuse of flow cell functionality. For example, in a single workflow, a flow cell can be used for tag fragmentation and then for amplification and sequencing. For another example, a flow cell can be reused for multiple cycles of transposome complex binding and tag fragmentation. These example flow cells can improve efficiency, enable indexing of tag-fragmented fragments, and / or enable enrichment.

[0007] Other examples of flow cells disclosed herein include photoactivated surface chemicals. These example flow cells enable spatial positioning control during surface preparation and / or methods occurring on the flow cell surface. Therefore, these example flow cells can improve efficiency and / or enable flow cell (or spatial) indexing (rather than indexing of single tagged fragmented DNA fragments).

[0008] Other examples of flow cells disclosed herein utilize heat, light, or pH changes to activate transposome complexes in predetermined locations / regions of the flow cell. Through selective and sequential activation of transposome complexes, multiple DNA samples can be sequentially introduced into the flow cell and exposed to tag fragmentation at corresponding predetermined locations / regions. Thus, cluster generation for a particular sample occurs in a specific predetermined region. This allows for spatial indexing of samples because each region includes fragments or clusters of different DNA samples. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] By referring to the following detailed description and accompanying drawings, the features of the examples of the present disclosure will become apparent, wherein like reference numerals correspond to similar but possibly not identical parts. For the sake of brevity, reference numerals or features having previously described functions may or may not be described in conjunction with other drawings in which they appear.

[0010] Figure 1 is a top view of the flow cell;

[0011] Figure 2A yes Figure 1 A cross-sectional view of a flow channel architecture of a flow cell comprising recessed portions separated by gap regions;

[0012] Figure 2B yes Figure 1 A cross-sectional view of another flow channel architecture of a flow cell comprising a single lane without recessed portions separated by gap regions;

[0013] 3A to 3H is a chemical flow diagram or chemical structure illustrating the visible light building block pairs;

[0014] Figure 4 is a schematic flow chart depicting one example of a method involving reusing a flow cell surface for multiple applications, including tag fragmentation and amplification;

[0015] Figure 5 is a schematic flow chart depicting another example of a method involving reusing a flow cell surface for multiple applications, including tag fragmentation and amplification;

[0016] Figure 6 is a schematic flow chart depicting still another example of a method involving reusing a flow cell surface for multiple applications, including tag fragmentation, enrichment, and amplification;

[0017] Figure 7 is a schematic flow chart depicting yet another example of a method involving reusing a flow cell surface for multiple applications including tag fragmentation, enrichment, and amplification

[0018] Figure 8is a schematic flow chart depicting still another example of a method involving reusing a flow cell surface for multiple applications, including enrichment of methylated bacterial DNA;

[0019] 9A to 9D are schematic diagrams that together depict a method for selectively attaching tagged fragmentation entities (e.g., transposome complexes) to predetermined areas of a flow cell using photoactivated surface chemistry, wherein Fig.9A depicts the selective attachment of transposome complexes to a first predetermined region upon exposure to light, Fig. 9B depicts the introduction of a first DNA sample and the tag fragmentation of the first DNA sample at a first predetermined region, Fig. 9C Depicting the removal of a transposase from a transposome complex at a first predetermined region, and Fig.9D depicts selective attachment of the transposome complex at a second predetermined region upon exposure to light;

[0020] Fig. 10A depicts a flow cell having different regions for performing different applications, wherein at least one region is photoactivated;

[0021] Fig. 10B depicts another flow cell having different regions for performing different applications, wherein at least one region is photoactivated;

[0022] Fig. 10C depicts still another flow cell having different regions for performing different applications, wherein at least one region is photoactivated;

[0023] FIG. 11A to FIG. 11D are schematic diagrams that together depict a method of selectively accessing a tag fragmentation entity (e.g., a transposome complex) at a predetermined region of a flow cell using a removable coating, wherein Fig.11A Depicting the introduction of a first DNA sample into a flow cell having a removable coating covering a transposome complex, Fig. 11B Depicting selectively removing a removable coating from a first predetermined region and tagging and fragmenting a first DNA sample in the first predetermined region, Fig. 11C Depicting the removal of a transposase from a transposome complex at a first predetermined region, and Fig.11D depicts introducing a second DNA sample into the flow cell, selectively removing the removable coating from the second predetermined region, and tag fragmenting the second DNA sample at the second predetermined region;

[0024] FIG. 12A to FIG. 12D are schematic diagrams that together depict a method for selectively releasing a tagged fragmentation entity (e.g., a transposome complex) at a predetermined region of a flow cell using an encapsulated complex, wherein Fig. 12ADepicting introducing a first DNA sample and an encapsulated complex into a flow cell, selectively releasing a tag fragmentation entity from the encapsulated complex at a first predetermined region, and tag fragmenting the first DNA sample at the first predetermined region, Fig. 12B Depicts the removal of the first DNA sample and the untagged fragmented portion of the transposase from the transposome complex across the flow cell, Fig. 12C Depicts the introduction of fresh transposase to improve the transposome complex, Fig.12D Depicting introducing a second DNA sample and the encapsulated complex into a flow cell, selectively releasing the tag fragmentation entity from the encapsulated complex at a second predetermined region, and tag fragmenting the second DNA sample at the second predetermined region;

[0025] FIG. 13A to FIG. 13D are schematic diagrams that together depict a method for selectively activating tagged fragmentation entities (eg, transposome complexes) in predetermined regions of a flow cell using heat, wherein Fig.13A depicts introducing a first DNA sample into a flow cell and tag fragmenting the first DNA sample in a first predetermined region when exposed to heat; Fig. 13B Depicted is the removal of transposase from the transposome complex across the flow cell. Fig. 13C Describes the introduction of fresh transposase to improve the transposome complex, and Fig.13D depicts introducing a second DNA sample into the flow cell and tag fragmenting the second DNA sample in a second predetermined region upon exposure to heat;

[0026] FIG. 14A to FIG. 14D depicts various examples of transposome complexes that can be used in various examples of the methods disclosed herein;

[0027] Fig.15A is a schematic top view of a lane of a flow cell having different target primers patterned at different regions along the lane;

[0028] Fig. 15B yes Fig.15A an enlarged cross-sectional view and a perspective view of a portion of any one region of a flow cell lane of the invention, wherein a target primer is attached within a recessed portion of the flow cell lane, and wherein a transposome complex containing a complementary spatial tag is depicted in one of the recessed portions;

[0029] Fig.16A depicts a binding complex comprising a DNA sample bound to a transposome complex containing a spatial tag, which is passivated by a hydrophobic polymer; and

[0030] Fig. 16B The bound complex passivated by the antifouling agent is depicted. DETAILED DESCRIPTION

[0031] Some examples of flow cells disclosed herein include surface chemicals for fixing transposome complexes and primers to the surface of the flow cell. By incorporating such surface chemicals, the flow cell can be reused for specific applications. Tag fragmentation on the flow cell generates DNA sample fragments (i.e., library fragments of a larger DNA sample) on the same surface where amplification and sequencing of the fragments occur. This eliminates the need for DNA sample preparation that leaves the flow cell to generate library fragments, and thus provides a more streamlined and efficient method. Some methods using these example flow cells also enable library fragment indexing and / or enrichment.

[0032] Other examples of flow cells disclosed herein include photoactivated surface chemistries. This enables spatial localization / positional control of surface chemistry activation, thereby enabling selective surface preparation and / or reaction initiation.

[0033] Still other examples of flow cells disclosed herein include using heat, light or pH changes to activate transposome complexes in predetermined areas of the flow cell. This enables control over where samples are seeded and amplified, and thus enables the use and identification of multiple samples through spatial indexing.

[0034] definition

[0035] Unless otherwise indicated, the terms used herein should be understood to have their ordinary meanings in the relevant art. Several terms used herein and their meanings are listed below.

[0036] As used herein, the singular forms "a", "an", and "the" include both the singular and the plural, unless the context clearly dictates otherwise. As used herein, the term "comprising" is synonymous with "including", "containing", or "characterized by", and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.

[0037] The references to "one example", "another example", "example", etc. throughout this specification mean that the specific elements (e.g., features, structures, compositions, configurations, and / or characteristics) described in conjunction with the example are included in at least one example described herein and may or may not be present in other examples. In addition, it should be understood that the elements used in any example may be combined in various examples in any suitable manner, unless the context clearly indicates otherwise.

[0038] The terms "substantially" and "approximately" as used throughout this disclosure (including the claims) are used to describe and illustrate small fluctuations, such as those caused by variations in processing. For example, these terms can refer to less than or equal to ±5% of a specified value, such as less than or equal to ±2% of a specified value, such as less than or equal to ±1% of a specified value, such as less than or equal to ±0.5% of a specified value, such as less than or equal to ±0.2% of a specified value, such as less than or equal to ±0.1% of a specified value, such as less than or equal to ±0.05% of a specified value.

[0039] Adaptor: an oligonucleotide sequence that can be fused to a nucleic acid molecule, for example, by connection or tag fragmentation. Suitable adaptor lengths can be in the range of about 10 nucleotides to about 100 nucleotides or about 12 nucleotides to about 60 nucleotides or about 15 nucleotides to about 50 nucleotides. Adaptors may include any combination of nucleotides and / or nucleic acids. In some examples, the adaptor may include an amplification domain, for example, having a universal nucleotide sequence, such as a P5 or P7 sequence, which can be used as a starting point for template amplification and cluster generation. In other examples, the adaptor may include a sequence complementary to at least a portion of a primer (including a universal nucleotide sequence) bound to the surface of a circulation cell. In the latter example, the adaptor sequence may hybridize with a primer bound to the surface of a complementary circulation cell during amplification and cluster generation. In some examples, the adaptor may also include a sequencing primer sequence (i.e., a sequencing binding site) or a sequencing sample index (i.e., a barcode sequence). Combinations of different adaptors may be incorporated into nucleic acid molecules (such as DNA fragments generated via tag fragmentation).

[0040] Amplification domain: A portion of an adaptor having a universal nucleotide sequence, such as a P5 or P7 sequence or a complementary sequence thereof, which can be used as a starting point for template amplification and cluster generation.

[0041] Corresponding to: When a primer "corresponds to" an amplification domain, the primer and the amplification domain may have the same sequence, such that a copy of the amplification domain generates a sequence complementary to the primer; or, when the amplification domain is introduced as part of an adaptor, they may have complementary sequences.

[0042] Deposition: Any suitable application technique, which may be manual or automated, and in some cases, results in modification of surface properties. Generally, deposition may be performed using vapor deposition techniques, coating techniques, grafting techniques, and the like. Some specific examples include chemical vapor deposition (CVD), spraying (e.g., ultrasonic spraying), spin coating, thick coating or dip coating, doctor blade coating, whipping dispensing, flow through coating, aerosol printing, screen printing, microcontact printing, inkjet printing, and the like.

[0043] Recess: refers to a discrete concave feature in a substrate or layer of a substrate (e.g., a patterned resin) having a surface opening at least partially surrounded by a gap region of the substrate or layer. A recess may have any of a variety of shapes at its opening in the surface, including, by way of example, circular, elliptical, square, polygonal, star-shaped (with any number of vertices), etc. A cross-section of a recess taken orthogonally to the surface may be curved, square, polygonal, hyperbolic, conical, angular, etc. Recesses may also have more complex shelf structures, such as ridges, step features, etc.

[0044] DNA sample: A polymeric form of nucleotides of any length, including deoxyribonucleotides, deoxyribonucleotide analogs, or complementary deoxyribonucleotides derived from an RNA (ribonucleic acid) sample. The DNA sample is double-stranded. The DNA sample may include naturally occurring DNA, which includes nitrogenous heterocyclic bases (nucleobases such as adenine, thymine, cytosine, and / or guanine), sugars (particularly deoxyribose, i.e., a sugar lacking the hydroxyl group present in the 2' position of the ribose) and a backbone containing phosphodiester bonds. Similar structures may have alternative backbone bonds, including any of a variety of backbone bonds known in the art.

[0045] The DNA sample can be genomic DNA (gDNA), which can be separated from one or more cells, body fluids (e.g., whole blood, blood spots, saliva) or tissues. gDNA can be prepared by lysing cells containing the DNA. Cells can be lysed under conditions that substantially maintain the integrity of the cell gDNA. In a specific example, thermal lysis can be used to lyse cells. In another specific example, cells exposed to alkaline pH can be used to lyse cells while causing relatively less damage to gDNA. Any of a variety of alkaline compounds can be used for lysis, including, for example, potassium hydroxide, sodium hydroxide, etc. In addition, relatively undamaged gDNA can be obtained from cells lysed by enzymes that degrade cell walls. Cells lacking cell walls naturally or due to enzyme removal can also be lysed by exposure to osmotic stress. Other conditions that can be used to lyse cells include exposure to detergents, mechanical destruction, ultrasonic treatment heat, pressure differences, such as French presses or Dounce homogenization. Reagents that stabilize gDNA can be included in cell lysates or separated gDNA samples, including, for example, nuclease inhibitors, chelating agents, salts, buffers, etc. The crude cell lysate containing gDNA can be used without further separation of gDNA. In one example, a whole blood sample can be lysed using a lysis buffer without inorganic salts, and the crude lysate can be exposed to specific processing steps to generate a composite crude lysate. This composite crude lysate can also be used as a DNA sample without further separation or purification.

[0046] Each: When used in reference to a collection of items, each identifies a single item in the collection but does not necessarily refer to every item in the collection. Exceptions may occur if explicitly disclosed or the context clearly dictates otherwise.

[0047] Flow cell: A container having a closed flow channel in which a reaction can be carried out, or a container having a channel open to the surrounding environment and in which a reaction can be carried out. A container having an open flow channel may be referred to as an open wafer flow cell in this article. Any example of a flow cell may include an inlet for delivering reagents to the channel and an outlet for removing reagents from the channel. In some examples, the flow cell enables detection of reactions occurring therein. For example, the flow cell may include one or more transparent surfaces that allow optical detection of arrays, optically labeled molecules, etc.

[0048] Flow channel: An area defined between two bound or otherwise attached components or an area defined within a lane so that it is open to the surrounding environment. A flow channel can selectively receive a liquid sample. In some examples, a flow channel can be defined between two patterned sequencing surfaces or between a patterned sequencing surface and a cover, and can therefore be in fluid communication with one or more components of a sequencing surface.

[0049] Fragment: A portion or fragment of a DNA sample. A "partially adapted fragment" is a portion or fragment of a DNA sample that has been fragmented by a tag and therefore includes an adaptor ligated to the 5' end of the DNA fragment. A "fully adapted fragment" is a portion or fragment of a DNA sample that has adaptors incorporated at both the 3' and 5' ends of the DNA fragment.

[0050] Primer: a single-stranded nucleic acid molecule that can hybridize with a target sequence, such as an adapter attached to a fragment. For example, a primer bound to the surface of a circulation cell can be used as a starting point for fragment amplification and cluster generation. As another example, a primer bound to the surface of a circulation cell can serve as a hybridization point for a spatial tag, and is therefore used for targeted attachment of a specific transposome complex and a DNA sample. For another example, a primer (e.g., a sequencing primer) that can hybridize with a fragment or a fragment amplicon can be introduced to initiate the synthesis of a new chain complementary to the fragment or fragment amplicon. Any primer can include any combination of nucleotides or their analogs. In some examples, a primer is a single-stranded oligonucleotide or polynucleotide. The primer length can be any number of bases long. In one example, each of the primer bound to the surface of a circulation cell and a sequencing primer is a short chain ranging from 10 to 60 nucleobases, or 20 to 40 nucleobases.

[0051] Tag fragmentation entity: Any component involved in the tag fragmentation process. This term may refer to the transposome complex, transposase, reagent, etc.

[0052] Tag-fragmentation: A process in which a DNA sample is cleaved / fragmented and labeled (e.g., tagged with adapters) for analysis. Tag-fragmentation is an in vitro transposition reaction.

[0053] Transferred strand and non-transferred strand: The term "transferred strand" refers to the sequence comprising the transferred portion of the transposon end. Similarly, the term "non-transferred strand" refers to the sequence comprising the non-transferred portion of the transposon end. The 3' end of the transferred strand is incorporated or transferred into the double-stranded fragment during tag fragmentation. The non-transferred strand is not incorporated or transferred into the double-stranded fragment during tag fragmentation. In one example, the transferred strand and the non-transferred strand comprise at least partially complementary portions covalently bound together.

[0054] Transposase: An enzyme that is capable of forming a functional complex with a composition containing a transposon end (e.g., a transposon, a transposon end, a transposon end composition) and catalyzing the insertion or transposition of the composition containing a transposon end into a double-stranded DNA sample incubated therewith, for example, in an in vitro transposition reaction (i.e., tag fragmentation). Transposases as described herein may also include integrases from retrotransposons and retroviruses. Although many of the examples described herein refer to Tn5 transposase and / or a hyperactive Tn5 transposase, it should be understood that any transposase that can insert a transposon end into a 5′-tag and fragment a DNA sample with sufficient efficiency for its intended purpose may be used.

[0055] Transpososome complex: An entity formed between a transposase and a double-stranded nucleic acid that includes a transposase integration recognition site. For example, a transpososome complex can be a transposase pre-incubated with a double-stranded transposon DNA under conditions that support the formation of a non-covalent complex. The double-stranded transposon DNA can include, for example, Tn5 DNA, a portion of Tn5 DNA, a transposon end composition, a mixture of transposon end compositions, or other double-stranded DNAs that can interact with a transposase (such as a hyperactive Tn5 transposase).

[0056] Transposon end: A double-stranded nucleic acid chain that exhibits only the nucleotide sequence necessary to form a complex with a transposase that functions in tag fragmentation ("transposon end sequence"). The double-stranded nucleic acid chain of the transposon end may include any nucleic acid or nucleic acid analog suitable for forming a functional complex with a transposase. For example, the transposon end may comprise natural DNA or a DNA analog (containing modified bases and / or backbone), and may comprise a nick in one or both strands.

[0057] Flow cell

[0058] Some examples of flow cells disclosed herein include biotin-containing linkers that enable the flow cell to be reused for different applications. Other examples of flow cells disclosed herein include visible light responsive members that enable the flow cell to be selectively activated.

[0059] Figure 1 An example of a flow cell 10 is depicted in top view in FIG. Figure 2A and Figure 2B Different examples of flow cell architectures are shown in .

[0060] A top view of an example of a flow cell 10 is shown in FIG. Figure 1 As shown in the reference Figure 2A and Figure 2B As discussed, some examples of flow cells 10 include two opposing substrates 12 and 12' or 14 and 14', each of which can be configured with a biotin-containing linker 16, 16' or a visible light-responsive member 18, 18'. Other example flow cells 10 include one substrate 12 or 14, which can be configured with a biotin-containing linker 16 or a visible light-responsive member 18, and a cover bonded to a portion of the substrate 12 or 14. Still other example flow cells 10 include one substrate 12 or 14, which can be configured with a biotin-containing linker 16 or a visible light-responsive member 18, and is not bonded to another component, but is open to the surrounding environment.

[0061] exist Figure 2A and Figure 2B In the example shown, the flow channel 20 is defined between two opposing substrates 12 and 12' or 14 and 14'. In other examples, the flow cell 10 includes a substrate 12 or 12' or 14 or 14', and a cover (not shown) attached to the substrate 12 or 12' or 14 or 14'. In these examples, the flow channel 20 is defined between the substrate 12 or 12' or 14 or 14' and the cover. In an open wafer format, the flow channel 20 can be defined by a lane 36 (see Figure 2B ).

[0062] exist Figure 2A and Figure 2B Different substrates 12 or 12' or 14 or 14' are shown.

[0063] exist Figure 2B In the example shown, the substrate 14, 14' is a single layer structure. Examples of suitable single layer structures for the substrate 14, 14' include epoxysiloxane, glass, modified or functionalized glass, polymeric materials (including acrylic, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, polytetrafluoroethylene (such as available from Chemours ), cycloolefins / cycloolefin polymers (COP) (such as those available from Zeon ), polyimide, nylon (polyamide), etc.), ceramic / ceramic oxides, silicon dioxide, fused silica or silicon dioxide-based materials, aluminum silicates, silicon and modified silicon (e.g., boron-doped p+ silicon), silicon nitride (Si3N4), silicon oxide (SiO2), tantalum pentoxide (Ta2O5) or other tantalum oxides (TaO x ), hafnium oxide (HfO2), carbon, metal, etc. In any of the examples disclosed herein, the substrate 14, 14' can be selected to be transparent to visible light.

[0064] exist Figure 2A In the examples shown, the substrate 12 or 12' is a multi-layer structure. The multi-layer structure of the substrate 12, 12' includes a base support 22, 22', and a patterned material 24, 24' on the base support 22, 22'. In any example disclosed herein, components of the substrate 12, 12' can be selected to be transparent to visible light.

[0065] The base support 22, 22' may be any of the examples described herein for the single layer structure of the substrate 14, 14'. The patterned material 24, 24' may be any material capable of being patterned with the recessed portions 26, 26'.

[0066] In one example, the patterning material 24, 24' can be an inorganic oxide that is selectively applied to the base support 22, 22' in a desired pattern, for example, via vapor deposition, aerosol printing, or inkjet printing. Examples of suitable inorganic oxides include tantalum oxide (e.g., Ta2O5), aluminum oxide (e.g., Al2O3), silicon oxide (e.g., SiO2), hafnium oxide (e.g., HfO2), etc. In another example, the patterning material 24, 24' can be a resin matrix material that is applied to the base support 22, 22' and then patterned. Suitable deposition techniques include chemical vapor deposition, dip coating, bubble coating, spin coating, spray coating, whipping distribution, ultrasonic spray coating, doctor blade coating, aerosol printing, screen printing, microcontact printing, etc. Suitable patterning techniques include photolithography, nanoimprint lithography (NIL), imprinting technology, embossing technology, molding technology, micro-etching technology, printing technology, etc. Some examples of suitable resins include polyhedral oligomeric silsesquioxane-based resins, non-polyhedral oligomeric silsesquioxane epoxy resins, poly(ethylene glycol) resins, polyether resins (e.g., ring-opened epoxides), acrylic resins, acrylate resins, methacrylate resins, amorphous fluoropolymer resins (e.g., available from Bellex ) and their combinations.

[0067] In one example, substrate 12, 12' or 14, 14' can be circular and have a diameter in the range of about 2mm to about 300mm, or can be a rectangular sheet or panel with a maximum size of up to about 10 feet (about 3 meters). In one example, substrate 12, 12' or 14, 14' is a wafer with a diameter in the range of about 200mm to about 300mm. The wafer can then be cut to form a separate flow cell substrate. In another example, substrate 12, 12' or 14, 14' is a die with a width in the range of about 0.1mm to about 10mm. Although example sizes have been provided, it should be understood that substrates 12, 12' or 14, 14' of any suitable size can be used. For example, a panel as a rectangular support can be used, which has a larger surface area than a 300mm circular wafer. The panel can then be cut to form a separate flow cell.

[0068] The flow cell 10 further includes a flow channel 20. Figure 1 Several flow channels 20 are shown, but it should be understood that any number of flow channels 20 (e.g., a single channel 20, four channels 20, etc.) may be included in the flow cell 10. Each flow channel 20 may be isolated from every other flow channel 20 in the flow cell 10 such that fluid introduced into any particular flow channel 20 does not flow into any adjacent flow channel 20.

[0069] At least a portion of the flow channel 20 may be defined in the substrate 12, 12' or 14, 14' using any suitable technique that depends in part on the material of the substrate 12, 12' or 14, 14'. In the case of an open chip flow cell, the entire flow channel 20 may be defined by the lane 36 defined in the substrate 12 or 14. In one example, at least a portion of the flow channel 20 is etched into a glass substrate, such as substrate 14, 14'. In another example, at least a portion of the flow channel 20 may be patterned into a resin matrix material of a multilayer structure using photolithography, nanoimprint lithography, or the like. In a closed form flow cell 10, a separate material (e.g., material 28) may be applied to the substrate 12, 12' or 14, 14' so that the separate material 28 defines at least a portion of the wall of the flow channel 20.

[0070] In one example, the flow channel 20 has a substantially rectangular configuration with rounded ends. The length and width of the flow channel 20 may be smaller than the length and width of the substrate 12, 12' or 14, 14', respectively, so that the portion of the substrate surface surrounding the flow channel 20 can be used to attach to another substrate 12, 12' or 14, 14' or to a cover, or to define the periphery of the open flow channel 20. In some cases, the width of each flow channel 20 can be at least about 1mm, at least about 2.5mm, at least about 5mm, at least about 7mm, at least about 10mm or more. In some cases, the length of each flow channel 54 can be at least about 10mm, at least about 25mm, at least about 50mm, at least about 100mm or more. The width and / or length of each flow channel 20 can be greater than, less than, or between the values ​​specified above. In another example, the flow channel 20 is a square (e.g., 10mm×10mm).

[0071] For example, when micro-contact, aerosol or inkjet printing is used to deposit a separate material 28 that partially defines the flow channel wall, the depth / height of each flow channel 20 can be as small as a few monolayers thick. In other examples, the depth / height of each flow channel 20 can be about 1 μm, about 10 μm, about 50 μm, about 100 μm or more. In one example, the depth / height may be in the range of about 10 μm to about 100 μm. In another example, the depth / height is about 5 μm or less. It should be understood that the depth / height of each flow channel 20 may also be greater than, less than, or between the values ​​specified above. For example, when recessed portions 26, 26' are used, the depth / height of the flow channel 20 may also vary along the length and width of the circulation pool 10.

[0072] Figure 2A The example flow cell architecture includes recessed portions 26, 26' separated by gap regions 34, 34'. Many different layouts of recessed portions 26, 26' can be envisioned, including regular, repeated and irregular patterns. In one example, recessed portions 26, 26' are arranged in a hexagonal grid to closely pack and improve density. Other layouts may include, for example, rectangular layouts, triangular layouts, etc. In some examples, the layout or pattern may be an xy format in rows and columns. In some other examples, the layout or pattern may be a repeated arrangement of recessed portions 26, 26' and gap regions 34, 34'. In other examples, the layout or pattern may be a random arrangement of recessed portions 26, 26' and gap regions 34, 34'.

[0073] The layout or pattern can be characterized with respect to the density (number) of recesses 26, 26' in a defined area. For example, the recesses 26, 26' can be approximately 2 million / mm. 2The density can be adjusted to different densities, including, for example, about 100 / mm 2 , about 1,000 pieces / mm 2 , about 100,000 pieces / mm 2 , about 1 million pieces / mm 2 , about 2 million pieces / mm 2 , about 5 million pieces / mm 2 , about 10 million / mm 2 , about 50 million / mm 2 or greater or lesser density. It should also be understood that the density can be between one of the lower and upper limits selected from the above ranges, or other densities (outside the given ranges) can be used. For example, a high density array can be characterized as having recesses 26, 26' separated by less than about 100 nm, a medium density array can be characterized as having recesses 26, 26' separated by about 400 nm to about 1 μm, and a low density array can be characterized as having recesses 26, 26' separated by more than about 1 μm.

[0074] The layout or pattern of the recessed portions 26, 26' may also be characterized according to or alternatively according to the average pitch or spacing (center-to-center spacing) from the center of one recessed portion 26, 26' to the center of an adjacent recessed portion 26, 26' or from the right edge of one recessed portion 26, 26' to the left edge of an adjacent recessed portion 26, 26' (edge-to-edge spacing). The pattern may be regular so that the coefficient of variation around the average pitch is small, or the pattern may be irregular, in which case the coefficient of variation may be relatively large. In either case, the average pitch may be, for example, about 50nm, about 0.1μm, about 0.5μm, about 1μm, about 5μm, about 10μm, about 100μm, or more or less. The average pitch of a particular pattern may be between a value selected from the lower limit value and a value selected from the upper limit value of the above range. In one example, the recessed portions 26, 26' have a pitch (center-to-center spacing) of about 1.5μm. While example average pitch values ​​have been provided, it should be understood that other average pitch values ​​may be used.

[0075] The size of each recess 26, 26' may be characterized by its volume, opening area, depth and / or diameter. For example, the volume may be about 1×10 -3 μm 3 to about 100 μm 3 In the range of, for example, about 1×10 -2 μm 3 , about 0.1μm 3 , about 1μm 3 , about 10μm 3, or larger, or smaller. For another example, the opening area can be about 1×10 -3 μm 2 to about 100 μm 2 In the range of, for example, about 1×10 -2 μm 2 , about 0.1μm 2 , about 1μm 2 , at least about 10 μm 2 , or greater, or less. For another example, the depth may be in the range of about 0.1 μm to about 100 μm, for example, about 0.5 μm, about 1 μm, about 10 μm, or greater, or less. For yet another example, the diameter or length and width may range from about 0.1 μm to about 100 μm, for example, about 0.5 μm, about 1 μm, about 10 μm, or greater or less.

[0076] Figure 2A An example flow cell architecture includes recesses 26, 26″ defined in corresponding lanes 36, 36′. Such an architecture may be ideal for the substrate 12 when used to form an open chip flow cell 10. Although not shown, it should be further understood that the recesses 26, 26′ may be defined on a substantially flat substrate surface (i.e., not in the lanes 36, 36′) and the material 28 may completely define the side walls of the closed flow cell 10.

[0077] Figure 2B The example flow cell architecture also includes lanes 36, 36' without recesses 26, 26'. In this example, channels 36, 36' extend just shorter than the full length and width of substrates 14, 14', so that gap regions 34, 34' are formed at the periphery of lanes 36, 36'. Figure 2B The flow cell architecture may be a method disclosed herein that can selectively attach tags to fragmented entities (see 9A to 9D ) or methods capable of selectively activating transposome complexes (see Figures 11, 12 and 13 series).

[0078] In one example, Figure 2A or Figure 2B The flow cell architecture shown in comprises a polymer hydrogel 32, 32' to which a visible light responsive member 18, 18' is attached.

[0079] The polymer hydrogel 32, 32' can be poly (N- (5-azidoacetamidopentyl) acrylamide-co-acrylamide) (PAZAM) or another acrylamide copolymer disclosed herein (e.g., poly (NN'-dimethylacrylamide), polyethylene glycol (PEG)-acrylate, PEG-diacrylate, PEG-amine, PEG-carboxylate, PEG-dithiol, PEG-epoxide, PEG-isocyanate, PEG-maleimide, cross-linked poly (methyl methacrylate) (PMMA), polyvinyl pyrrolidone (PVPON), polyvinyl alcohol (PVA), polyethylene oxide-polypropylene oxide block copolymer (PEO-PPO), poly (methacrylate hydroxyl) ... The invention can be applied to hydrogels of the present invention, for example, poly(lactic acid)-poly(ethylene glycol) block copolymers, poly(ethylene glycol)-poly(lactic acid-co-glycolic acid) block copolymers, poly(acrylic acid-co-vinyl sulfonic acid), poly(acrylamide-co-vinyl sulfonic acid), poly(L-aspartic acid), poly(asparagine), adipic acid dihydrazide-modified or aldehyde-modified poly(L-glutamic acid), bisacrylamide), or hydrogels based on one or more of polylysine, starch, agar, agarose, heparin, alginate, alginate sulfate, dextran sulfate, hyaluronic acid, pectin, carrageenan, gelatin, chitosan, cellulose and collagen, or combinations or mixtures thereof.

[0080] In one example, the polymer hydrogel 32, 32' comprises an acrylamide copolymer. In this example, the acrylamide copolymer has structure (I):

[0081]

[0082] in:

[0083] R A is an azide or tetrazine or any other functional group to which an alkyne, amino, alkenyl, alkyne, halogen, hydraarea, hydrazine, carboxyl, hydroxyl, tetrazole, nitrone, sulfate or thiol can be attached;

[0084] R B is H or optionally substituted alkyl;

[0085] R C , R D and R E are each independently selected from H and optionally substituted alkyl;

[0086] -(CH2) p - each of which may be optionally substituted;

[0087] p is an integer ranging from 1 to 50;

[0088] n is an integer in the range of 1 to 50,000; and

[0089] m is an integer in the range of 1 to 100,000.

[0090] A specific example of the acrylamide copolymer represented by structure (I) is poly(N-(5-azidoacetamidopentyl)acrylamide-co-acrylamide) (PAZAM).

[0091] One of ordinary skill in the art will recognize that the arrangement of recurring "n" and "m" features in structure (I) is representative and that the monomer subunits may be present in the polymer structure in any order (e.g., random, block, patterned, or a combination thereof).

[0092] The molecular weight of the acrylamide copolymer may be in the range of about 5 kDa to about 1500 kDa or about 10 kDa to about 10 MDa, or in one specific example may be about 312 kDa.

[0093] In some examples, the acrylamide copolymer is a linear polymer. In some other examples, the acrylamide copolymer is a lightly cross-linked polymer.

[0094] In some examples, the gel material can be a variation of structure (I). In one example, the acrylamide unit can be N, N-dimethylacrylamide. In another example, the acrylamide unit in structure (I) can be replaced by Replace, where R D , R E and R F are each H or C1-C6 alkyl, and R G and R H Each is a C1-C6 alkyl group (rather than H, as in the case of acrylamide). In this example, q can be an integer in the range of 1 to 100,000. In another example, in addition to the acrylamide units, N,N-dimethylacrylamide can also be used. In this example, in addition to the recurring "n" and "m" features, structure (I) can also include Where R D , R E and R F are each H or C1-C6 alkyl, and R G and R H Each is a C1-C6 alkyl group. In this example, q may be an integer in the range of 1 to 100,000.

[0095] As another example of a polymer hydrogel 32, 32', the recurring "n" feature in structure (I) may be replaced with a monomer including a heterocyclic azido group having structure (II):

[0096]

[0097] Where R 1 is H or C1-C6 alkyl; R2 is H or C1-C6 alkyl; L is a linker comprising a straight chain having 2 to 20 atoms selected from carbon, oxygen and nitrogen and 10 optional substituents on the carbon and any nitrogen atoms in the chain; E is a straight chain comprising 1 to 4 atoms selected from the group consisting of carbon, oxygen and nitrogen and optional substituents on the carbon and any nitrogen atoms in the chain; A is an N-substituted amide having H or C1-C4 alkyl attached to N; and Z is a nitrogen-containing heterocycle. Examples of Z include 5 to 10 carbon-containing ring members present as a single cyclic structure or a fused structure. Some specific examples of Z include pyrrolidinyl, pyridinyl or pyrimidinyl.

[0098] As yet another example, the gel material may include repeating units of each of structures (III) and (IV):

[0099]

[0100] Where R 1a , R 2a , R 1b and R 2b Each of R is independently selected from hydrogen, optionally substituted alkyl or optionally substituted phenyl; 3a and R 3b Each of L is independently selected from hydrogen, optionally substituted alkyl, optionally substituted phenyl or optionally substituted C7-C14 aralkyl; and each L 1 and L 2 are independently selected from an optionally substituted alkylene linker or an optionally substituted heteroalkylene linker.

[0101] As mentioned, in some examples, the polymer hydrogel 32, 32' has one member 18, 18' of a visible light responsive pair attached thereto. A "visible light responsive pair" refers to two or three reagents that undergo a coupling reaction when exposed to visible light. When the pair includes two reagents, one reagent is attached to the polymer hydrogel 32, 32' and the other reagent is attached to a tag fragmentation entity (e.g., a transposome complex), a primer, or another entity to be introduced to the surface of the flow cell. When the pair includes three reagents, one reagent is attached to the polymer hydrogel 32, 32', another reagent is attached to an entity to be introduced to the surface of the flow cell, and the third reagent is present in the formulation introduced when the coupling reagent is to be performed.

[0102] exist 3A to 3HExamples of visible light responsive pairs are shown in FIG. In each of these figures, R and R1 or R1 and R2 or bold indicates a moiety that is connected upon photoactivation. Any of these groups may be attached to the polymer hydrogel 32, 32' or the entity to be introduced to the surface of the flow cell. When a third entity is used in the coupling reaction, it may be introduced together with the entity to be introduced to the surface of the flow cell.

[0103] The first visible light responsive member 18, 18' may be attached to the polymer hydrogel 32, 32' via covalent bonding or non-covalent bonding. As an example, the first visible light responsive member 18, 18' may be attached to the R A Non-covalent bonding (eg, biotin-streptavidin) may be used, as long as neither member of the non-covalent binding pair can bind to another member of the visible light responsive pair.

[0104] In another example, Figure 2A The flow cell architecture shown includes a biotinylated polymer hydrogel 30, 30', which includes a biotin-containing linker 16, 16'. In these examples, the biotin is A A group (e.g., an azide, tetrazine, or other functional group that can be attached to an alkyne) is attached to the surface of a polymer hydrogel (e.g., 32, 32'). Biotin is attached to a linker, such as bicyclo[6.1.0]nonyne (BCN), which can be covalently attached to some RA groups. A combination of biotin and a linker is one example of a biotin-containing linker 16, 16'. In another example, streptavidin is attached to biotin, which is attached to a linker, which can be covalently attached to R A Some of the groups. In this example, the biotin-containing linker 16, 16' includes a linker, biotin and streptavidin. In order to form the biotinylated polymer hydrogel 30, 30', the biotin-containing linker 16, 16' can be added to the polymer hydrogel (e.g., 32, 32') before or after the polymer hydrogel (e.g., 32, 32') is applied to the recessed portion 26, 26'. Streptavidin can be part of the linker 16, 16', or added to the flow cell 10 before or at the same time as adding the biotinylated transposome complex or biotinylated primer to be connected to the linker 16, 16'.

[0105] In still other examples, the flow cell 10 does not include a visible light responsive member 18 , 18 ′ or a biotin-containing linker 16 , 16 ′.

[0106] In some of these examples, the transposome complex, such as Fig. 14C or Fig.14DThose shown in , can be directly bound to the RA groups of the polymer hydrogel 32, 32'. These example flow cells can include transposome complexes bound thereto, or these transposome complexes can be introduced as part of the method.

[0107] In other of these examples, the flow cell 10 includes a target primer capable of hybridizing to a portion of the transposome complex. Fig.15A and Fig. 15B The target primers are further described.

[0108] Reuse of flow cell surface

[0109] Some flow cells 10 can be reused for various applications. Example Methods (Ref. Figure 4 and Figure 5 ) including the use of multiple transposome complexes 38A ( Figure 4 and Fig.14A ) or 38B( Figure 5 or Fig. 14B ) generating at least partially adapted DNA sample fragments on the flow cell 10, wherein the transposome complexes are attached to the surface of the flow cell 10 within the flow channel 20 via a biotin-containing linker 16; cleaving the at least partially adapted DNA sample fragments such that the biotin-containing linker 16 remains attached to the surface; and one of the following: using the flow cell 10 for subsequent cycles of generating at least partially adapted DNA sample fragments; or using the flow cell 10 to amplify at least some of the previously cleaved and at least partially adapted DNA sample fragments.

[0110] These example methods utilize Figure 2A . More specifically, these flow cells 10 include: a substrate 12 having recesses 26 separated by gap regions 34; a polymer hydrogel (specifically, a biotinylated polymer hydrogel 30, 30') positioned within each of the recesses 26; and a plurality of transposome complexes 38A or 38B immobilized within each of the recesses 26 via a biotin-containing linker 16. In one example, each of the plurality of transposome complexes 38A, 38B is of a single type, including a transposon end 40, wherein a portion of a transferred strand 42 is hybridized with a portion of a non-transferred strand 44 or 44', wherein the transferred strand 42 includes a first amplification domain 45 and does not contain an index sequence. In another example, each of the plurality of transposome complexes 38A, 38B is of a single type, comprising a transposon end 40, wherein a portion of a transferred strand 42 is hybridized to a portion of a non-transferred strand 44 or 44′, wherein the transferred strand 42 comprises a first amplification domain 45 and further comprises an index sequence ( Figure 4 or Figure 5During repurposing, the newly added transposome complex 38A or 38B will include a different index sequence, allowing each sample to be uniquely indexed.

[0111] exist Figure 4 and Figure 5 In the example shown, the biotin-containing linker 16 includes a graftable group (e.g., BCN or any RA group) and biotin. As noted, streptavidin 60 can be part of the linker 16 or can be added to the flow cell 10 before or simultaneously with the addition of the transposome complexes 38A, 38B.

[0112] exist Figure 4 , Fig.14A , Figure 5 and Fig. 14B In each of the FIGs. 3 and 4, a single transposome complex 38A, 38B is shown. However, it should be understood that the transposome complex 38A, 38B will form dimers in solution and when attached to the flow cell surface. It should be understood that for simplicity, in FIGs. 3 and 4, a single transposome complex 38A, 38B is shown. However, it should be understood that the transposome complex 38A, 38B will form dimers in solution and when attached to the flow cell surface. Figure 4 and Figure 5 A single transposome complex is shown in FIG. The dimer form of some of the transposome complexes 38A and 38B is shown in FIG. Figure 6 Shown in.

[0113] exist Figure 4 and Fig.14A In the example of FIG. 4 , each of the transposome complexes 38A includes a transposase 46 non-covalently bound to a transposon end 40. Each transposon end 40 is a double-stranded nucleic acid strand, one strand ME of which is part of a transferred strand 42 and the other strand ME′ of which is a non-transferred strand 44. In other words, the transposon end 40 includes a portion of a transferred strand 42 hybridized to a non-transferred strand 44.

[0114] The transferred strand 42 includes a 5' terminal functional group 48. In this example, the 5' terminal functional group 48 is biotin. The transferred strand 42 also includes a first amplification domain 45 and a sequencing primer sequence 47 attached to one strand ME of the transposon end 40. The strand ME of the transposon end 40 is located at the 3' end of the transferred strand 42.

[0115] In this example, the first amplification domain 45 has a first amplification domain 45 that is coupled to a subsequently introduced adaptor 50 (which, when hybridized to the transferred strand 42, forms a forked adaptor 50', such as Figure 4 D) of the second amplification domain 49 (e.g., P5′) but has a different sequence from that to be introduced into the flow cell 10 (e.g., Figure 4The first amplification domain 45 and the primer 55 together with the second amplification domain 49 and another primer 57 (e.g., P5 or P15) to be introduced to the surface of the flow cell enable amplification of the DNA sample fragments generated during tag fragmentation.

[0116] The P5 primer sequence is one of the following:

[0117] P5#1: 5′→3′

[0118] AATGATACGGCGACCACCGAGAUCTACAC(SEQ.ID.NO.1);

[0119] P5#2: 5' → 3'

[0120] AATGATACGGCGACCACCGAGAnCTACAC(SEQ.ID.NO.2)

[0121] wherein "n" is inosine in SEQ.ID.NO.2; or

[0122] P5#3: 5' → 3'

[0123] AATGATACGGCGACCACCGAGAnCTACAC(SEQ.ID.NO.3)

[0124] wherein "n" is ene-thymidine (ie, ene-dT) in SEQ.ID.NO.3.

[0125] The P5' sequence is the complementary sequence of any P5 example.

[0126] The P7 primer sequence can be any of the following:

[0127] P7#1: 5′→3′

[0128] CAAGCAGAAGACGGCATACGAnAT(SEQ.ID.NO.4)

[0129] P7#2: 5' → 3'

[0130] CAAGCAGAAGACGGCATACnAGAT(SEQ.ID.NO.5)

[0131] P7#3: 5' → 3'

[0132] CAAGCAGAAGACGGCATACnAnAT(SEQ.ID.NO.6)

[0133] wherein "n" is 8-oxoguanine in each of SEQ.ID.NOS.4-6.

[0134] It should be understood that other sequences can be used for amplification domains 45, 49 (e.g., P7, P5') and primers 55, 57 (e.g., P7, P5), as long as the combination can perform the desired amplification. Therefore, the nomenclature P5, P5' and P7 are provided as examples, and the corresponding domains 45, 49 and / or primers 55, 57 are not limited to the specific sequences described herein. As an example, P15, PA, PB, PC or PD primers can be used.

[0135] The sequence of the P15 primer is:

[0136] P15: 5′→3′

[0137] AATGATACGGCGACCACCGAGAnCTACAC(SEQ.ID.NO.7)

[0138] wherein "n" is allyl-T (ie, a thymine nucleotide analog having an allyl functional group).

[0139] The above other primer sequences (PA-PD) include:

[0140] PA5'→3'

[0141] GCTGGCACGTCCGAACGCTTCGTTAATCCGTTGAG(SEQ.ID.NO.8)

[0142] PB 5'→3'

[0143] CGTCGTCTGCCATGGCGCTTCGGTGGATATGAACT(SEQ.ID.NO.9)

[0144] PC 5'→3'

[0145] ACGGCCGCTAATATCAACGCGTCGAATCCGCAACT(SEQ.ID.NO.10)

[0146] PD 5'→3'

[0147] GCCGCGTTACGTTAGCCGGACTATTCGATGCAGC(SEQ.ID.NO.11)

[0148] Although not shown in the example sequences of PA-PD, it is understood that any of these sequences may include a cleavage site 52 at any point in the strand, such as uracil, 8-oxoguanine, allyl-T, diol, etc. The sequences of the first amplification domain 45 / primer 55 and the second amplification domain 49 / primer 57 may be selected to have orthogonal cleavage sites (i.e., one cleavage site is insensitive to the cleavage agent used for the other cleavage site) so that after amplification, either the forward strand or the reverse strand may be cleaved, leaving the other of the reverse strand or the forward strand for sequencing.

[0149] Primers 55 and 57 may also include a polyT sequence at the 5′ end of the primer sequence. In some examples, the polyT region includes 2 to 20 T bases. As specific examples, the polyT region may include 3, 4, 5, 6, 7 or 10 T bases.

[0150] Sequencing primer sequences 47, 53 (the latter being part of adaptor 50) have sequences different from each other, which are respectively bound to sequencing primers introduced into flow cell 10 after tag fragmentation and amplification. As an example, sequencing primer sequence 47 can bind to a sequencing primer that initiates the synthesis of a new chain complementary to the forward strand fragment / fragment amplicon, and sequencing primer sequence 53 can bind to a sequencing primer that initiates the synthesis of a new chain complementary to the reverse strand fragment / fragment amplicon.

[0151] The transposon end 40 of each transposome complex 38A includes a strand ME that is hybridized with a strand ME', respectively. Therefore, strands ME, ME' are complementary. The double-stranded transposon end 40 is capable of complexing with a transposase 46. As an example, strands ME, ME' of the transposon end 40 can be related but not identical 19 base pairs (bp) of outer terminal (e.g., strand ME) and inner terminal (e.g., strand ME') sequences (these sequences serve as substrates for Tn5 transposase activity), or chimeric terminals recognized by wild-type or mutant Tn5 transposases, or R1 terminals (e.g., strand ME) and R2 terminals (strand ME') recognized by MuA transposases.

[0152] exist Figure 4At the beginning of the illustrated method (at A), the transposome complex 38A is attached to the biotinylated polymer hydrogel 30 in the recess 26. Avidin or streptavidin 60 can be used to attach the 5′ terminal functional group 48 (which in this example is biotin) to the biotinylated polymer hydrogel 30. As an example, before the complex 38A is introduced into the flow cell 10 and incubated, the avidin or streptavidin 60 can be pre-attached to the 5′ terminal functional group 48; or the avidin or streptavidin 60 can be introduced into the flow cell 10 with the 5′ biotinylated transposome complex 38A and incubated; or the avidin or streptavidin 60 can be introduced into the flow cell 10 and incubated with the biotinylated polymer hydrogel 30, and then can be The 5′-biotinylated transposome complex 38A is added and incubated; alternatively, avidin or streptavidin 60 and biotin are pre-attached to each other and then introduced into the flow cell 10, wherein the biotin is attached to the surface of the polymer hydrogel via some RA groups (directly or via a linker), and then the 5′-biotinylated transposome complex 38A can be introduced into the flow cell 10 containing the streptavidin-biotin binding linker 16 as part of the biotinylated polymer hydrogel 30.

[0153] In this exemplary method, fully adapted DNA fragments are generated by: introducing a DNA sample 54 and a tag fragmentation buffer into a flow cell 10 (see B); performing tag fragmentation of the DNA sample 54 using a plurality of transposome complexes 38A (see B); removing the transposase 46 from each of the plurality of transposome complexes 38A (see C); replacing the non-transferred strand 44 of each of the plurality of transposome complexes 38A with an adaptor 50, the adaptor comprising: a ME portion complementary to the transferred strand 42; a sequence, for example, ME'; a sequencing primer sequence 53; an index sequence 51; and a second amplification domain 49, which is complementary to a primer 47 that is or will be fixed in each recess 26 of the flow cell 10, thereby dehybridizing the non-transferred strand 44 and hybridizing the adapter 50 with a portion of ME of the transferred strand 42 of each of the multiple transposome complexes 38A (thereby forming a forked adapter 50', see D); and performing gap-filling ligation to attach the DNA sample fragments to the corresponding forked adapters 50' (see D).

[0154] like Figure 4As shown in B in FIG. 1 , a DNA sample (shown as fragmented at reference numeral 54) is introduced into the flow cell 10 for tag fragmentation. The DNA sample 54 may be introduced together with a tag fragmentation buffer, which may include water, an optional co-solvent (e.g., dimethylformamide), a metal cofactor of the transposase (e.g., magnesium acetate), and a buffer salt (e.g., tris(hydroxymethyl)aminomethane (Tris or TRIS) acetate, pH 7.6). In one example, the optional co-solvent may be present in an amount of up to about 11%, the metal cofactor may be present in a concentration ranging from about 3 mM to about 10 mM, and the buffer salt may be present in a concentration ranging from about 7 mM to about 12 mM.

[0155] When the DNA sample 54 is introduced into the flow cell 10 including the transposome complex 38A, the DNA sample 54 is fragmented and the 5′ ends of the two chains of the duplex fragments 58, 58′ are connected to the corresponding 3′ ends of the transferred chain 42 of the transposome complex 38A. The tag fragmentation and connection can be performed at a temperature of 30°C or higher. In one example, the temperature can be in the range of 30°C to about 55°C. In another example, the temperature can be in the range of 35°C to about 45°C. The 3′ ends of the duplex fragments 58, 58′ are not connected to the 5′ ends of the non-transferred chains 44. Therefore, there is a gap G (such as 5′) between the 3′ end of each DNA fragment chain 58, 58′ and the 5′ end of the corresponding non-transferred chain 44. Figure 4 In one example, each gap G is nine (9) base pairs long.

[0156] like Figure 4 As shown in C in FIG. 3 , the transposase 46 is then removed from the complex 38A, which is now attached to the fragments 58, 58′, respectively, via the transfer strand 42. Removal of the transposase 46 can be accomplished, for example, using sodium dodecyl sulfate (SDS) or a protease, or by heating the flow cell to about 60° C. When heat is used, some example methods involve introducing a wash solution into the flow cell 10; and heating the flow cell 10 containing the wash solution to about 60° C. An example wash solution is an aqueous solution comprising a buffer (e.g., Tris), a salt (e.g., sodium chloride, sodium citrate, etc.), a surfactant (e.g., TWEEN polysorbate), and / or a chelating agent (e.g., EDTA). In one example, the wash solution comprises water, a salt in a concentration range of about 25 mM to about 50 mM, a surfactant in an amount ranging from about 0.01 wt % to about 0.1 wt %, and an optional chelating agent. The wash solution may have a relatively high pH, ​​for example ranging from about 7 to about 10.

[0157] The non-transferred strand 44 of each of the plurality of transposome complexes 38A is replaced with the adapter 50, which produces Figure 4As shown between C and D, the adapter 50 includes a sequence ME" complementary to the ME portion of the transferred strand 42, a sequencing primer sequence 53, an index sequence 51, and a second amplification domain 49 (e.g., P5') complementary to a primer 47 (e.g., P5) that is or will be fixed within each recess 26 of the flow cell 10. The index sequence 51 is a unique barcode sequence that can be used for identification and indexing of DNA sample fragments. The non-transferred strand 44 is dehybridized, and the adapter 50 is hybridized to a portion of the ME of the transferred strand 42 to produce a forked adapter 50'.

[0158] Gap-filling ligation is then performed to attach the DNA sample fragments 58, 58' to the sequence ME"' of the corresponding forked adaptor 50' (see Figure 4 D). Gap filling ligation can be performed with any suitable gap filling ligase (e.g., tTaq608 polymerase, T7 exo minus polymerase, etc.) and any suitable ligase (e.g., E. coli DNA ligase, T4 DNA ligase, etc.) in combination with a solution of nucleotides. Gap filling ligation can be performed at a temperature ranging from about 37° C. to about 50° C. for about 5 minutes.

[0159] As a result of the gap-filling ligation, a fully-fit DNA fragment is attached to the flow cell 10. The fully-fit fragment is shown at D and includes a first amplification domain 45 (e.g., P7) at one end and a second amplification domain 49 (e.g., P5′) at the other end, with the corresponding DNA fragment 58, 58′ located therebetween.

[0160] The perfectly adapted DNA fragment is then cleaved by introducing an appropriate cleavage agent for the cleavage site 52. For example, uracil can be cleaved by uracil-DNA glycosylase (UDG), inosine can be cleaved by Endo IV, 8-oxoguanine can be cleaved by 8-oxoguanine DNA glycosylase, and vicinal diol bonds can be cleaved by oxidation (such as treatment with a periodate reagent).

[0161] By cleaving the perfectly adapted DNA sample fragment at the cleavage site 52, the biotin-containing linker 16 remains attached to the surface, as Figure 4 As shown in F.

[0162] The cut fully adapted DNA fragments are transported to the holding container 26'. Figure 4. In one example, the holding container 26' is a well or chamber patterned into the substrate 12 or 14. In this example, the holding container 26' is in fluid communication with the flow channel 20, but is separate from the flow channel 20. The holding container 26' does not include the polymer hydrogel 30. Alternatively, the holding container may not be in the flow cell, such as in a box on an instrument that receives the flow cell. Within the holding container 26', the cut fully adapted DNA fragments are denatured to form single-stranded, fully adapted DNA fragments 56A, 56B. In one example, the denaturation occurs in NaOH or Tris HCl and heated (e.g., at about 90°C).

[0163] After cleaving the fully adapted DNA sample fragments so that the biotin-containing adapter 16 remains attached to the flow cell surface, and before using the flow cell 10, the method further includes removing streptavidin 60 from the biotin-containing adapter 16. The removal of streptavidin (or avidin) 60 is Figure 4 As shown at F in FIG.

[0164] To remove streptavidin 60, a biotin-streptavidin cleavage composition can be introduced into the flow cell 10. Examples of biotin-streptavidin cleavage compositions include about 95% formamide and about 10 mM ethylenediaminetetraacetic acid (EDTA), or about 10% to about 50% by volume of a formamide reagent and the balance a salt buffer. At a suitable reaction temperature, these cleavage compositions disrupt the biotin-streptavidin interaction, thereby releasing any substance (e.g., streptavidin, 5′ terminal functional group 48 (biotin)) attached to the biotin of the biotin-containing linker 16. Alternatively, heat washing with biotin and / or desthiobiotin causes the newly added biotin and / or desthiobiotin to compete with the already bound biotin. By disrupting the biotin-streptavidin interaction, streptavidin 60 and the 5' terminal functional group 48 (biotin) are removed, leaving biotin-BCN (ie, one example of a biotin-containing linker 16) attached to the polymer hydrogel 30.

[0165] The flow cell 10 can then be used for subsequent cycles of generating new fully adapted DNA sample fragments (e.g., Figure 4 F in returns to A), or is used to amplify at least some previously cut and fully adapted DNA sample fragments (e.g., single-stranded fully adapted sample fragments 56A, 56B).

[0166] When the flow cell 10 is used to generate a subsequent cycle of new fully adapted DNA sample fragments, the subsequent cycle of generating fully adapted DNA sample fragments includes: introducing a new plurality of transposome complexes 38A into the flow channel 20, whereby at least some of the new plurality of transposome complexes 38A are attached to at least some of the biotin-containing adapters 16 within the flow channel 20; introducing a new DNA sample 54 and a new tag fragmentation buffer into the flow channel 20; and repeating the tag fragmentation, the removal of the transposase 46, the replacement of the non-transferred strand 44 with the adapter 50, and the gap-filling ligation with the new DNA sample. The repeated steps can be performed in the same manner as described herein. For example, streptavidin 60 can be added together with the transposome complexes 38A (which include biotin as the 5′ terminal group 48) to attach them to the biotin-containing adapter 16. The flow cell 10 can be repeatedly used to prepare single-stranded fully adapted fragments 56A, 56B from several different DNA samples.

[0167] When the flow cell 10 is used to amplify at least some of the previously cleaved and fully adapted DNA sample fragments, the method involves attaching first and second primers 55, 57 (e.g., P7, P5) to at least some of the biotin-containing adapters 16 within the flow channel 20 (see Figure 4 and introducing the previously cut and fully adapted DNA sample fragments 56A, 56B in single-stranded form into the flow cell 10.

[0168] Although reference is made to the P5 and P7 primers, it should be understood that other sequences may be used for primers 55, 57 as long as the combination is capable of achieving the desired amplification of the single-stranded fully adapted DNA sample fragments 56A, 56B. Primers 55, 57 include a 5' terminal group 48' (biotin in this example) so that they can be attached to the biotin-containing linker 16 via streptavidin 60. Any avidin / streptavidin technique described herein for attaching the transposome complex 38A to the biotinylated polymer hydrogel 30 can be used to attach primers 55, 57.

[0169] Once primers 55, 57 are connected, the single-stranded fully adapted sample fragments 56A, 56B can be transported back to the flow channel 20, where each fragment will be inoculated in the recess 26 and undergo amplification. The second amplification domain 49 (e.g., P5') of the single-stranded fully adapted sample fragments 56A, 56B hybridizes with the primer 57 in the recess 26. High-fidelity DNA polymerase is used to copy sample fragments 56A, 56B from the hybridized primer 57 (e.g., P5) by 3' extension. The original sample fragments 56A, 56B are denatured, so that the copies are fixed around the recess 26. Isothermal bridge amplification or some other forms of amplification can be used to amplify fixed copies. For example, the replicated template loops back to hybridize with adjacent complementary primers 55 (e.g., P7), and the polymerase replicates the replicated template to form a double-stranded bridge, which is denatured to form two single strands. The two chains loop back and hybridize with adjacent complementary primers and extend again to form two new double-stranded loops. This process is repeated for each template copy by isothermal denaturation and amplification cycles, thereby generating dense clusters of amplicon clones in the recess 26. Each cluster of double-stranded bridges is denatured. In one example, the antisense strand is removed by specific base cutting, leaving the forward template strand. This example of clustering is called bridge amplification and is an example of an executable amplification. It should be understood that other amplification techniques can be used.

[0170] Sequencing can then be performed. In one example, sequencing by synthesis is performed by introducing a sequencing primer followed by an incorporation mixture comprising labeled nucleotides. Each instance of nucleotide incorporation can be detected using optical imaging.

[0171] After sequencing, the biotin-streptavidin cleavage composition can be reintroduced to remove the primers 55, 57 and the amplicons and nascent chains attached thereto. This leaves the biotin-containing adapter 16 within the recess 26 ready for another cycle (similar to Figure 4 F).

[0172] exist Figure 5 and Fig. 14B In the example of , each of the transposome complexes 38B includes a transposase 46 non-covalently bound to a transposon end 40. Each transposon end 40 is a double-stranded nucleic acid strand, wherein one strand ME is part of a transferred strand 42 and wherein the other strand ME' is part of a non-transferred strand 44'. In other words, the transposon end 40 includes a portion of the transferred strand 42 hybridized with a portion of the non-transferred strand 44'. Thus, the strands ME, ME' are complementary. Any of the strands ME, ME' described herein may be used.

[0173] The transferred strand 42 includes a 5' terminal functional group 48. In this example, the 5' terminal functional group 48 is biotin. The transferred strand 42 also includes a sequencing primer sequence 47 attached to one strand ME of the transposon end 40, and a first amplification domain 45. Although not shown, the transferred strand 42 may also include an index sequence between the sequencing primer sequence 47 and the first amplification domain 45. The strand ME of the transposon end 40 is positioned at the 3' end of the transferred strand 42.

[0174] In this example, the non-transferred strand 44' is an adaptor that also includes a sequencing primer sequence 53 (attached to strand ME'), an index sequence 51, and a second amplification domain 49 (e.g., P5') that is complementary to a primer 57 (e.g., P5) to be immobilized within each of the recesses 26 of the flow cell 10 (see Figure 5 G in.

[0175] The first amplification domain 45 has a different sequence than the second amplification domain 49, but has the same sequence as one primer 55 to be introduced into the flow cell 10 (e.g., Figure 5 G in). The second amplification domain 49 is a complement of another primer 57 to be attached to the flow cell 10. The first amplification domain 45 and primer 55 together with the second amplification domain 49 and primer 57 enable amplification of the DNA sample fragments 54 generated during tag fragmentation. Any of the amplification domains 45, 49 can be used in this example as long as they generate single-stranded, fully adapted DNA fragments 56A, 56B, and any of the primers 55, 57 can be used in this example as long as they can amplify the generated single-stranded, fully adapted DNA fragments 56A, 56B.

[0176] The sequencing primer sequences 47 , 53 have sequences different from each other, and these sequences are respectively bound to the sequencing primers introduced into the flow cell 10 after the tag fragmentation and amplification.

[0177] The index sequence 51 is a unique barcode sequence that can be used for DNA sample fragment identification and indexing. In another example, the index sequence is a unique molecular index (UMI).

[0178] exist Figure 5At the beginning of the illustrated method (at A), the transposome complex 38B is attached to the biotinylated polymer hydrogel 30 in the recess 26. Avidin or streptavidin 60 can be used to attach the 5′ terminal functional group 48 (which in this example is biotin) to the biotinylated polymer hydrogel 30. As an example, before the complex 38B is introduced into the flow cell 10 and incubated, the avidin or streptavidin 60 can be pre-attached to the 5′ terminal functional group 48; or the avidin or streptavidin 60 can be introduced into the flow cell 10 with the 5′ biotinylated transposome complex 38B and incubated; or the avidin or streptavidin 60 can be introduced into the flow cell 10 and incubated with the biotinylated polymer hydrogel 30, and then can be The 5′-biotinylated transposome complex 38B is added and incubated; alternatively, avidin or streptavidin 60 and biotin are pre-attached to each other and then introduced into the flow cell 10, wherein the biotin is attached to the surface of the polymer hydrogel via some RA groups (directly or via a linker), and then the 5′-biotinylated transposome complex 38B can be introduced into the flow cell 10 containing the streptavidin-biotin binding linker 16 as part of the biotinylated polymer hydrogel 30.

[0179] In this example method, fully adapted DNA fragments are generated by: introducing a DNA sample 54 and a tag fragmentation buffer into a flow channel 10 (see B); performing tag fragmentation of the DNA sample 54 using a plurality of transposome complexes 38B (see B); removing the transposase 46 from each of the plurality of transposome complexes 38B (see C); and performing gap-filling ligation to attach the DNA sample fragments to corresponding non-transferred strands 44′ (e.g., forked adapters 50′, see D).

[0180] like Figure 5 As shown in FIG. 1B , a DNA sample 54 (shown as fragments 58, 58′) is introduced into the flow cell 10 for tag fragmentation. The DNA sample 54 can be compared with a reference Figure 4 The described tag fragmentation buffer was introduced together.

[0181] When the DNA sample 54 is introduced into the flow cell 10 including the transposome complex 38B, the DNA sample 54 is fragmented and the 5′ ends of both strands of the duplex fragments 58, 58′ are ligated to the corresponding 3′ ends of the transferred strand 42 of the transposome complex 38B. Fragmentation and ligation can be performed as described in reference Figure 4 The 3' ends of the fragments 58, 58' are not attached to the non-transferred strand 44', and thus a corresponding gap G is formed.

[0182] like Figure 5 As shown in C in FIG. 3 , transposase 46 is then removed from complex 38B, which is now attached to fragments 58, 58′, respectively, via transferred strand 42. Removal of transposase 46 can be performed as follows: Figure 4 Said completion.

[0183] Gap-fill ligation is then performed to attach the DNA sample fragments 58, 58' to the non-transferred strand 44' (see Figure 5 As a result of the gap-filling ligation, a fully adapted DNA fragment (having the first amplification domain 45 at one end and the second amplification domain 49 at the other end) is attached to the flow cell 10.

[0184] The fully adapted DNA fragments are then cleaved by introducing a suitable cleavage agent for the cleavage site 52. Any of the exemplary cleavage agents disclosed herein may be used. By cleaving the fully adapted DNA sample fragments at the cleavage site 52, the biotin-containing linker 16 remains attached to the surface, such as Figure 5 As shown in F.

[0185] The cut fully adapted DNA fragments are transported to the holding container 26'. Figure 5 In the holding container 26 ', the cut fully adapted DNA fragments are denatured to form single-stranded, fully adapted DNA fragments 56A, 56B. In one example, the denaturation occurs in NaOH or Tris HCl and heat.

[0186] After cleaving the fully adapted DNA sample fragments so that the biotin-containing adapter 16 remains attached to the flow cell surface, and before using the flow cell 10, the method further includes removing streptavidin 60 from the biotin-containing adapter 16. The removal of streptavidin 60 is Figure 5 As shown at F in the figure, you can use Figure 4 The biotin-streptavidin cleavage composition removes streptavidin 60 and the 5' terminal functional group 48 (biotin) of the transferred strand 42.

[0187] The flow cell 10 can then be used for subsequent cycles of generating new fully adapted DNA sample fragments (e.g., Figure 5 F in returns to A), or is used to amplify at least some previously cut and fully adapted DNA sample fragments (e.g., single-stranded fully adapted sample fragments 56A, 56B).

[0188] When the flow cell 10 is used to generate a subsequent cycle of new fully adapted DNA sample fragments, the subsequent cycle of generating fully adapted DNA sample fragments includes: introducing a new plurality of transposome complexes 38B into the flow channel 20, whereby at least some of the new plurality of transposome complexes 38B are attached to at least some of the biotin-containing adapters 16 within the flow channel 20; introducing a new DNA sample 54 and a new tag fragmentation buffer into the flow channel 20; and repeating the tag fragmentation, the removal of the transposase 46, and the gap-filling connection with the new DNA sample 54. The repeated steps can be performed in the same manner as described herein. For example, streptavidin 60 can be added together with the transposome complexes 38B to attach them to the biotin-containing adapter 16. The flow cell 10 can be repeatedly used to prepare fully adapted fragments 56A, 56B from several different DNA samples. In these examples, the fully adapted fragments 56A, 56B from several different DNA samples can be stored in the holding container 26' and then introduced when amplification is required for all fragments.

[0189] When the circulation pool 10 is used to amplify at least some previously cut and fully adapted DNA sample fragments, the method involves attaching the first primer and the second primer 55, 57 to at least some biotin-containing linkers 16 within the flow channel 20 (see G); and introducing the previously cut and fully adapted DNA sample fragments 56A, 56B in single-stranded form into the circulation pool 10.

[0190] Although reference is made to P5 and P7 primers, it should be understood that other sequences may be used for primers 55, 57 as long as the combination is capable of achieving the desired amplification of single-stranded fully adapted DNA sample fragments 56A, 56B. Primers 55, 57 include biotin at the 5' end so that they can be attached to the biotin-containing linker 16 via streptavidin 60. Any avidin / streptavidin technique described herein for attaching the transposome complex 38B to the biotinylated polymer hydrogel 30 may be used to attach primers 55, 57.

[0191] Once primers 55, 57 are ligated, the single-stranded fully adapted sample fragments 56A, 56B can be transported back to the flow channel 20 where each fragment will be seeded in the recess 26 and undergo the same Figure 4 The amplification described above can then be sequenced. After sequencing, the biotin-streptavidin cleavage composition can be reintroduced to remove the primers 55, 57 and the amplicons and nascent chains attached thereto. This makes the biotin-containing adapter 16 in the recess 26 ready for another cycle.

[0192] exist Figure 4 and Figure 5In the example shown, single-stranded fully adapted DNA sample fragments 56A, 56B may alternatively be prepared as described herein and then introduced into another type of flow cell having primers 55, 57 attached to a non-biotinylated polymer hydrogel 32 in the recess 26. This is a single-use flow cell and the surface is not reused after amplification and sequencing. In these examples, the 5′ terminal functional group 48 of the transposome complex 38A, 38B may be any functional group capable of attaching to the RA group of the polymer hydrogel 32.

[0193] The flow cell 10 including the biotinylated polymer hydrogel 30 can also be used for enrichment. Enrichment enables the isolation and analysis of a target portion of a DNA sample 54, for example, a specific gene variant in a given sample. For this type of analysis, the target portion or region of interest can be enriched, for example, which helps to separate the target portion from the rest of the DNA sample 54. This enables sequencing reads to be specific to the target portion. The enrichment techniques disclosed herein utilize hybridization and capture of the labeled fragmented DNA fragments 58, 58' corresponding to the target portion on the flow cell. Figure 6 , Figure 7 and Figure 8 An example is shown in .

[0194] exist Figure 6 and Figure 8 In each example shown, the plurality of transposome complexes may include a first transposome complex 38C comprising a first amplification domain 45C (e.g., P7) and a second transposome complex 38D comprising a second amplification domain 49D (e.g., P5). These transposome complexes 38C, 38D are Fig. 14C This is shown in more detail in Fig. 14C In each complex, one of 38C and 38D forms a dimer and in Figure 6 and Figure 8 In the present study, two of the same complex 38C or 38D form a dimer.

[0195] like Fig. 14C As shown, each of the first and second transposome complexes 38C, 38D includes a transposase 46 non-covalently bound to a transposon end 40C, 40D. In this example, each transposon end 40C, 40D is a double-stranded nucleic acid strand, wherein one strand (e.g., ME) is part of a transferred strand 42C or 42D, and the other strand (e.g., ME') is part of a non-transferred strand 44C or 44D. Any of the example strands of the transposon end 40 (e.g., ME and ME') described herein may be used.

[0196] exist Fig. 14C In the example shown, the transferred strand 42C includes a protein capable of non-covalently attaching to avidin / streptavidin (in Figure 6 40C), a first amplification domain 45C, and a sequencing primer sequence 47C attached to one strand of the transposon end 40C (which is located at the 3′ end of the transferred strand 42C). In some examples, the transferred strand 42C includes an index sequence between the first amplification domain 45C and the sequencing primer sequence 47C. Similar to the transferred strand 42C, the transferred strand 42D includes a 5′ terminal functional group 48D (in this case, biotin) capable of covalently attaching to avidin / streptavidin, a second amplification domain 49D, and a sequencing primer sequence 47D attached to one strand (ME) of the transposon end 40D (which is located at the 3′ end of the transferred strand 40D).

[0197] The first and second amplification domains 45C and 49D of the transposome complexes 38C and 38D have sequences different from each other (e.g., P7 and P5), but have sequences identical to the first primer and the second primer to be introduced into the biotinylated polymer hydrogel 30 (in Figure 6 The first amplification domain 45C, the transposome complex 38C and the primer 55 together with the second amplification domain 49D, the transposome complex 38D and the primer 57 enable amplification of DNA sample fragments 58, 58' generated during tag fragmentation. Examples of suitable sequences of the first amplification domain 45C / primer 55 and the second amplification domain 49D / primer 57 include any of the examples described herein.

[0198] Although not shown, it should be understood that Figure 6 and Figure 8 In each example shown, the plurality of transposome complexes may alternatively include a first transposome complex 38E comprising a first amplification domain 45E (e.g., P7) and a second transposome complex 38F comprising a second amplification domain 49F (e.g., P5). These transposome complexes 38E, 38F are shown in more detail in Fig.14D In. Fig.14D In the embodiment of the present invention, one of each complex 38E, 38F forms a dimer, but it should be understood that two of the same complex 38E or 38F can form a dimer.

[0199] like Fig.14DAs shown, each of the first and second transposome complexes 38E, 38F includes a transposase 46 non-covalently bound to a transposon end 40E, 40F. In this example, each transposon end 40E, 40F is a double-stranded nucleic acid strand, wherein one strand (e.g., ME) is part of a transferred strand 42E or 42F, and the other strand (e.g., ME') is part of a non-transferred strand 44E or 44F. Any of the example strands of the transposon end 40 (e.g., ME and ME') described herein may be used.

[0200] In the transposome complex 38E, the transferred strand 42E includes a first amplification domain 45E and a sequencing primer sequence 47E attached to one strand ME of the transposon end 40E. In some examples, the transferred strand 42F includes an index sequence between the first amplification domain 45E and the sequencing primer sequence 47E. The strand ME of the transposon end 40E is located at the 3′ end of the transferred strand 42E. Similar to the transferred strand 42E, the transferred strand 42F of the transposome complex 38F includes a second amplification domain 49F and a sequencing primer sequence 47F attached to one strand ME′ of the transposon end 40F. The strand ME of the transposon end 40F is located at the 3′ end of the transferred strand 42F.

[0201] The first and second amplification domains 45E, 49F of the transposome complexes 38E, 38F have sequences different from each other (e.g., P7 and P5), but have sequences identical to the first primer and the second primer to be introduced into the biotinylated polymer hydrogel 30 (in Figure 6 The first amplification domain 45E, the transposome complex 38E and the primer 55 together with the second amplification domain 49F, the transposome complex 38F and the primer 57 enable amplification of DNA sample fragments 58, 58' generated during tag fragmentation. i) An example of a suitable sequence for the first amplification domain 45E is the same as the sequence of the first amplification domain 45C / primer 55 described herein, and ii) An example of a suitable sequence for the second amplification domain 49F is the same as the sequence of the second amplification domain 49D / primer 57 described herein.

[0202] Similar to sequencing primer sequences 47C and 47D, sequencing primer sequences 47E and 47F have sequences different from each other, which are respectively bound to sequencing primers introduced into the flow cell after tag fragmentation and amplification.

[0203] The transposome complexes 38E, 38F are configured to be asymmetrically attached to the flow cell surface (e.g. Fig.11A). Thus, one of these complexes (e.g., complex 38E) includes a 3′ terminal group 48E for attachment to the surface of the flow cell, and another of these complexes (e.g., complex 38F) includes a 5′ terminal group 48F for attachment to the surface of the flow cell. Fig.14D As depicted, the non-transferred chain 44E of the complex 38E includes a 3' terminal group 48E, and the transferred chain 42F of the complex 38F includes a 5' terminal group 48F. The 3' terminal group 48E and the 5' terminal group 48F can be any functional group capable of being covalently or non-covalently attached directly or indirectly to the surface functional groups of the polymer hydrogel 30, 32, and will therefore depend on the surface functional groups of the polymer hydrogel 30, 32. In one example, the polymer hydrogel 32 includes an azido or tetrazine surface group, and the 3' terminal group 48E and the 5' terminal group 48F each include a terminal alkyne (e.g., a hexynyl group) or an internal alkyne, wherein the alkyne is part of a cyclic compound (e.g., bicyclo[6.1.0]nonyne (BCN)). In another example, the biotinylated polymer hydrogel 30 is present in the recess 26 of the flow cell 10, and each of the 3' terminal group 48E and the 5' terminal group 48F is biotin. In these examples, additional streptavidin or avidin 60 is added to indirectly attach the biotin groups to each other, as described herein. Still other reactive pairs (e.g., polymer hydrogel and RA of 48) include tetrazine / TCO, amine / carboxylic acid, amine / alkyl hydrocarbon, thiol / ene or thiol / carboxylic acid. Tag fragmentation involving transposome complexes 38E, 38F can be performed in the same manner as described herein for transposome complexes 38C, 38D.

[0204] Return to reference Figure 6 In this example method, a fully adapted DNA sample fragment is generated (e.g., Figure 6 56C, 56D) shown in D) includes introducing the DNA sample 54 and the tag fragmentation buffer into the flow cell 10 (see Figure 6 C); using multiple transposome complexes 38C, 38D to perform tag fragmentation of DNA sample 54 (see Figure 6 C); removing the transposase 46 (not shown) from each of the plurality of transposome complexes 38C and 38D; and performing an extension reaction (see Figure 6 C). The introduction of DNA sample 54, tag fragmentation and removal of transposase 46 can be as described herein. Figure 4 Proceed as described.

[0205] When SDS or another chaotropic detergent has been used to remove the transposase, a wash solution can be flushed through the flow channel prior to initiating the extension reaction. This removes chaotropic detergent that may interfere with downstream enzyme activity.

[0206] To initiate the extension reaction, an extension amplification mixture is introduced into the circulation pool 10. Examples of extension amplification mixtures include nucleotides, recombinases, polymerases, and auxiliary proteins. The extension amplification mixture may also include a buffer (e.g., Tris), an enzyme, a stabilizer, a metal cofactor, a surfactant (e.g., TWEEN polysorbate), and / or a cosolvent (e.g., glycerol, dimethylformamide, etc.). ExAMP reagents available from Illumina Inc. are examples of suitable extension amplification mixtures.

[0207] When the extension amplification mixture is introduced, the flow cell 10 can be at a temperature of up to about 60° C. (eg, about 38° C.).

[0208] At the beginning of the extension reaction, the non-transferred strands 44C, 44D are dehybridized. By performing an extension reaction using an extension amplification mixture, an additional sequence (adapter) is added to the 3' end of the partially adapted fragment (fragment 58, 58'). The extension reaction involves adding nucleotides from the 3' end of the DNA fragment 58, 58' in a template-dependent manner using the corresponding transferred strands 42C, 42D as templates. The extension is performed by Figure 6 . Thus, DNA fragment 58 is extended along transfer strand 42D to generate a complementary portion of sequencing primer sequence 47D and second amplification domain 49D attached to DNA fragment 58; and DNA fragment 58′ is extended along transfer strand 42C to generate a complementary portion of sequencing primer sequence 47C and first amplification domain 45C attached to DNA fragment 58′. The sequence generated by the extension reaction fully adapts partially adapted fragments 58, 58′ (i.e., tagged fragments that are not connected, extended, etc.). At least some of the fully adapted fragments generated along transposome complex 38D include the first amplification domain 45C (e.g., P7) at one end and the complement of the second amplification domain 49D (e.g., P5′) at the other end. At least some of the fully adapted fragments generated along transposome complex 38C include the second amplification domain 49D (e.g., P5) at one end and the complement of the first amplification domain 45C (e.g., P7′) at the other end.

[0209] The fully adapted DNA fragment is then cleaved by introducing a suitable cleavage agent for cleavage site 52. Cleavage can be performed as described in reference Figure 4 Double-stranded, fully adapted DNA fragments are released from the flow cell surface.

[0210] Figure 6 The method shown then includes generating an enriched sample by: denaturing the fully adapted DNA sample fragments to generate single-stranded, fully adapted DNA sample fragments 56C, 56D (see D), some of which include target regions (i.e., regions of interest for analysis); transporting the single-stranded, fully adapted DNA sample fragments 56C, 56D to an enrichment container 26″′; and introducing a biotinylated capture probe 62 into the enrichment container 26″′, whereby some of the single-stranded, fully adapted DNA sample fragments 56C, 56D having target regions hybridize with the biotinylated capture probe 62, respectively, to form enriched complexes 64 (see FIG. Figure 6 ), and some other single-stranded, fully adapted DNA sample fragments 56 that do not have the target region remain unattached. The enrichment container 26″′ can be a separate compartment on the flow cell 10, or can be outside the flow cell 10, such as in a box on an instrument that receives the flow cell 10.

[0211] The biotinylated capture probe 62 comprises i) one or more single-stranded deoxyribonucleic acid sequences complementary to the target region, and ii) a biotin at the terminus for subsequent attachment to avidin / streptavidin 60 on the flow cell surface. In its simplest form, the biotinylated capture probe 62 comprises a single-stranded sequence complementary to the target region of the DNA sample, with a biotin at the terminus.

[0212] like Figure 6 As shown, an example of a biotinylated capture probe 62 is a polynucleotide bottle brush polymer structure. The polynucleotide bottle brush polymer structure is described in International Publication No. WO 2022 / 220748, which is incorporated herein by reference in its entirety. In short, the polynucleotide bottle brush polymer includes a substantially linear polynucleotide backbone, including a sequence of nucleotides connected to each other by phosphodiester bonds, and a polynucleotide side chain of a nucleobase of a nucleotide connected to the polynucleotide backbone by one or more covalent bonds or by one or more non-covalent bonds. The sequence of the side chain can be complementary to the target region, so the side chain can be used as a probe for hybridizing only those single-stranded, fully adapted DNA sample fragments 56C, 56D containing the target region. In some examples, the side chain includes a coordinated complementary sequence to enhance the enrichment intensity. In other examples, the side chain can be an interlocking probe. In other examples, the side chain can be conjugated to a peptide rather than a linear polynucleotide backbone.

[0213] The enrichment vessel 26'" is heated and the biotinylated capture probe 62 (eg, one or more of its side chains) will hybridize to the target region of some of the single-stranded, fully-matched DNA sample fragments 56C, 56D. This forms an enriched complex 64.

[0214] Although in Figure 6 2, but after cleavage of the fully adapted DNA sample fragments 56, 56C, 56D, the biotin-containing adapter 16 remains attached to the surface within the recess 26. The 5'-terminal biotin 48 also remains attached via streptavidin 60. Therefore, after cleavage and before amplification of the enriched sample using the flow cell 10, the method further includes removing the streptavidin 60 from the biotin-containing adapter 16. The removal of the streptavidin 60 can be as follows Figure 4 The resulting surface is similar to Figure 4 and Figure 5 F in.

[0215] Figure 6 The method shown then includes supplementing the flow channel 20 with streptavidin 60 (see Figure 6 E); transporting the enriched sample (from the enrichment container 26″′) to the flow channel 20 including the supplemented streptavidin 60, whereby the enriched complex 64 is attached to the biotin-containing linker 16 (via the biotin on the probe 62), and the single-stranded, fully adapted DNA sample fragment 56 without the target region remains unattached; introducing a wash solution into the flow channel 20 to remove the single-stranded, fully adapted DNA sample fragment 56 without the target region; releasing the single-stranded, fully adapted DNA sample fragment 56C, 56D with the targeted region from the biotinylated capture probe 62; and transporting the single-stranded, fully adapted DNA sample fragment 56C, 56D with the targeted region to the holding container 26″′ (see Figure 6 G in.

[0216] exist Figure 6 , at F, the biotin of the enriched complex 64 is attached to the surface-bound avidin / streptavidin 60, and the non-complexed fragments 56 remain free in the solution. These free and non-complexed fragments 56 are removed from the flow channel 20 by flushing a wash solution through the flow channel 20. The enriched complex 64 (and thus the fragments 56C, 56D having the target region) remain in the flow channel 20. By removing the fragments 56 that do not include the target region, the remaining sample is enriched.

[0217] The bound single-stranded, fully adapted DNA sample fragments 56C, 56D (with the target region) can then be released from the biotinylated capture probe 62; and transported to the holding container 26"' (see Figure 6G in). Release involves dehybridization from the probe 62 and can be performed in the presence of NaOH or Tris-HCl and heating. When the single-stranded, fully adapted DNA sample fragments 56C, 56D are removed and moved into the container 26", the probe 62 will remain attached to the surface-bound streptavidin 60.

[0218] While the fragments 56C, 56D are in the holding container 26", the method further includes removing the streptavidin 60 from the biotin-containing linker 16 in the flow channel 20 (see Figure 6 and attaching the first and second primers 55, 57 to at least some of the biotin-containing connectors 16 within the flow channel 20 (see Figure 6 I). These two processes can be referred to in this article Figure 4 It will be appreciated that primers 55, 57 are biotinylated for attachment to linker-bound avidin / streptavidin 60.

[0219] Fragments 56C, 56D are then transported from holding container 26" back to flow channel 20 where they will hybridize with one of primers 55, 57 and undergo amplification as described herein. Two amplicons of one of the single-stranded, fully matched DNA sample fragments 56C, 56D are shown in FIG. Figure 6 At J in the middle.

[0220] Reference now Figure 7 , depicts another example of enrichment. This may be desirable for blood, saliva, or a small cancer panel.

[0221] In this example, a biotinylated polymer hydrogel 30 (within a biotin-containing linker 16) is present in the recess 16 of the flow cell 10 (see Figure 7 In this example, each of the plurality of transposome complexes 38A is of a single type, including a transposon end 40 in which a portion of a transferred strand 42 is hybridized to a non-transferred strand 44. The transposome complex 38A is a reference Figure 4 Those described can be immobilized on the flow cell 10 using the avidin / streptavidin 60 described herein.

[0222] In this example, the tag fragments are formed into partially adapted DNA sample fragments 58, 58', so that there is a gap G between the 3' end of each DNA fragment chain 58, 58' and the 5' end of the corresponding non-transferred chain 44 (eg, Figure 7(as shown in C in FIG. 1 ). The formation of these fragments 58, 58' involves introducing a DNA sample 54 and a tag fragmentation buffer into the flow channel 20; performing tag fragmentation of the DNA sample 54 using a plurality of transposome complexes 38A; and removing the transposase 46 from each of the plurality of transposome complexes 38A. The resulting fragments are partially adapted to the first amplification domain 45 (e.g., P7) of the transferred strand 42 of the transposome complex 38A.

[0223] Without gap-filling ligation, the partially adapted fragments (still with the non-transferred strand 42 attached) can be cleaved at the cleavage site 52 using a cleavage agent disclosed herein. The method then further includes denaturing the partially adapted DNA sample fragments to each other and removing the non-transferred strand 44 to generate single-stranded partially adapted DNA sample fragments 68A, 68B (shown in FIG. Figure 7 D in FIG. 5 ), wherein some of the single-stranded portions of the adapted DNA sample fragment 68A include the target region (shown as Figure 7 ROI (region of interest) in D in the figure); transporting the single-stranded, partially adapted DNA sample fragments 68A, 68B to an enrichment container 26'', the enrichment container 26'' comprising a surface-bound adapter 66 having a second amplification domain 49 (e.g., P5) and a region complementary to the target region, whereby some single-stranded, partially adapted DNA sample fragments 68A having the target region ROI are hybridized with the surface-bound adapter 66, respectively, and some other single-stranded, partially adapted DNA sample fragments 68B without the target region ROI remain unattached (see D); introducing a washing solution into the enrichment container 26'' to remove the single-stranded partially adapted DNA sample fragment 68B without the target region ROI; and performing an extension reaction along the surface-bound adapter 66 to generate fully adapted DNA sample fragments (see the bottom of D). As described herein, the enrichment container 26'' may be on the circulation pool 10 or not in the circulation pool, for example in a box.

[0224] In this example, the second amplification domain 49 has the same sequence as the primer 57 (e.g., P5) to be introduced into the circulation pool 10, and the resulting fully adapted fragments 56E, 56F will include the complement 45' of the first amplification domain 45 (e.g., P7) of the transposome complex 38A. Therefore, the fully adapted fragments 56E, 56F shown at the bottom of D include 45' (e.g., P7'), which can hybridize with the circulation pool primer 55 (e.g., P7) to initiate amplification. In the enrichment container 26'", the extension reaction can be carried out as described herein. The resulting fully adapted fragments 56E, 56F can then be cut from the container 26'".

[0225] When the fragments 56E, 56F are in the enrichment container 26'", the method also includes removing the streptavidin 60 from the biotin-containing linker 16 in the flow channel 20; and attaching the first and second primers 55, 57 (e.g., P7, P5) to at least some of the biotin-containing linkers 16 in the flow channel 20 (see Figure 7 F). These two processes can be referred to in this article Figure 4 Specifically, streptavidin 60 is first removed to simultaneously remove the 5′-terminal biotin remaining after cleavage of the partially adapted DNA fragment. Then, streptavidin 60 is supplemented before primers 55 and 57 are attached (see Figure 7 E). It will be appreciated that primers 55, 57 are biotinylated for attachment to linker-bound avidin / streptavidin 60.

[0226] In enrichment ( Figure 7 D) and primers 55 and 57 are attached ( Figure 7 F), the fragments 56E, 56F are then transported from the enrichment container 26" back to the flow channel 20 where they will hybridize with one of the primers P7, P5 and undergo amplification as described herein.

[0227] Figure 8 The exemplary method shown in FIG. 1 includes capturing a plurality of biotinylated dDpn1 70 ( Figure 8 A and B in the figure); the DNA sample is introduced into the flow cell 10, whereby the methylated bacterial DNA 72 in the DNA sample is captured by the biotinylated dDpn1 70 ( Figure 8 C); a wash solution is introduced into the flow channel 20 to remove the uncaptured DNA sample therefrom (not shown); the methylated bacterial DNA 72 is released from the biotinylated dDpn1 70, so that the biotin-containing linker 16 remains attached to the surface ( Figure 8 The released methylated bacterial DNA 72 is transported to the holding container 26"' ( Figure 8 D); when the released methylated bacterial DNA 72 is in the holding container 26", the streptavidin 60 is supplemented from the biotin-containing linker 16 (replacing or removing and replacing the streptavidin used in AC); a plurality of biotinylated transposome complexes 38C, 38D are introduced into the flow channel 20, whereby the plurality of biotinylated transposome complexes 38C, 38D are attached to some of the biotin-containing linkers 16 ( Figure 8F); and introducing a plurality of biotinylated primers 55, 57 into the flow channel 20, whereby the plurality of biotinylated primers 55, 57 are attached to some other biotin-containing adapters 16; and transporting the released methylated bacterial DNA 72 back into the flow channel 20 containing the biotinylated transposome complexes 38C, 38D and the biotinylated primers 55, 57 for tag fragmentation and amplification ( Figure 8 G and H in ).

[0228] The biotinylated dDpn1 70 is attached to the flow cell surface via streptavidin 60 and a biotin-containing linker 16. When a DNA sample is introduced into the flow cell 10, the methylated bacterial DNA 72 within the DNA sample is captured by the biotinylated dDpn1 70.

[0229] After the methylated bacterial DNA 72 is captured, any of the wash solutions disclosed herein may be used to remove non-captured DNA samples from the flow cell 10 .

[0230] Once the uncaptured DNA sample and wash solution have been removed, the Mg-containing 2+ , proteinase K or SDS solution to release the methylated bacterial DNA 72 from the biotinylated dDpn1 70. Proteinase K or SDS may release the biotinylated dDpn1 70 and the methylated bacterial DNA 72. In the latter case, the biotinylated dDpn1 70 will be separated from the methylated bacterial DNA 72.

[0231] In a specific example, Mg 2+ Used to release the captured methylated bacterial DNA 72. In this example, after the methylated bacterial DNA 72 is released, it is transported to the holding container 26", and the biotinylated dDpn1 70 is removed. In one example, the biotinylated dDpn1 70 is removed together with the streptavidin 60. In this example, a biotin-streptavidin cleavage composition can be introduced into the flow cell 10, which will destroy the biotin-streptavidin interaction, thereby releasing the biotinylated dDpn1 70 from the streptavidin 60 and releasing the streptavidin from the biotin-containing linker 16. In another example, the biotinylated dDpn1 70 can include another cleavable group, and the cleavage agent of the group can be used to remove the biotinylated dDpn1 70. As an example, the cleavage agent can be an enzyme cleavage agent or an acid. Proteinase K or SDS can be used to remove the biotinylated dDpn1 70.

[0232] Supplementation of streptavidin 60, introduction of transposome complexes 38C, 38D and biotinylated primers 55, 57, tag fragmentation and amplification can be performed as described herein.

[0233] Photoactivated flow cell surface

[0234] Other examples of flow cells 10 include visible light responsive members 18 that enable at least a portion of the flow cell surface to be selectively activated at a desired time to perform a desired reaction. These flow cells 10 can be used in a method that includes introducing a tag fragmentation entity (e.g., transposome complex 38) having a first visible light responsive member 18A attached thereto into a flow cell 10 having a second visible light responsive member 18B attached thereto; and when the tag fragmentation entity is present in the flow cell 10, exposing a predetermined area of ​​the flow cell 10 to visible light, thereby coupling the first visible light responsive member 18A and the second visible light responsive member 18B and attaching the tag fragmentation entity to the flow cell 10 at the predetermined area. Several example methods are described in 9A to 9D and FIG. 10A to FIG. 10C Shown in.

[0235] In these examples, the tag fragmentation entity 74 can be any of the transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F described herein. The process (e.g., gap-filling ligation, extension reaction, etc.) performed to generate the perfectly adapted DNA fragments 56 will depend on the type of transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F used.

[0236] Also in these examples, visible light responsive members 18A, 18B may be referenced herein. 3A to 3H Any example of the described visible light responsive member 18. It should be understood that the visible light responsive member 18A can be used to replace the 5' terminal functional group 48 in the complex 38A or 38B; the visible light responsive member 18A can be used to replace the 5' terminal functional groups 48C, 48D in the corresponding complexes 38C, 38D; or, the visible light responsive member 18A can be used to replace the 5' terminal functional group 48F of the complex 38F and the 3' terminal functional group 48E of the complex 38E.

[0237] exist 9A to 9D In the example shown, the flow cell 10 is similar to Figure 2A The flow cell is shown (although the base support 22 is not shown) and includes a visible light responsive member 18B attached to a polymer hydrogel 32 in the recesses 26. In this example, the flow cell 10 has the same surface chemistry in each of the recesses 26. Alternatively, a Figure 2BThe flow cell 10 is shown, and the visible light responsive member 18B can be positioned along the lane 36. Although not shown, each flow cell recess 26 also has a primer 55, 57 attached to the polymer hydrogel 32.

[0238] When the tag fragmentation entity 74 is introduced into the flow channel 20, a specific area of ​​the flow cell 10 (e.g. Fig.9A In area 76A, Fig.9D The region 76B in the flow cell 10 (eg, the region 76B in the flow cell 10) is exposed to visible light (from the light source 78), and the exposed visible light responsive members 18A, 18B undergo a coupling reaction to attach the tag fragmentation entity 74 to the recess 26. Any region of the flow cell 10 that is not exposed to visible light (eg, Fig.9A 76B, 76C in the flow channel 20 will not have the tag fragmentation entity 74 attached, and can therefore be activated for subsequently introduced samples. This allows different DNA samples to be attached to different regions 76A, 76B, 76C of a single flow channel 20, and thus enables spatial indexing to be used for sample identification. The data generated during sequencing can be demultiplexed using analysis of different regions 76A, 76B, 76C.

[0239] exist FIG. 10A to FIG. 10C In the example shown, the flow cell 10 is similar to Figure 2A The flow cell is shown (except that the base support 22 is not shown) and includes a visible light responsive member 18B attached to a polymer hydrogel 32 in some of the recesses 26. Alternatively, a Figure 2B The flow cell 10 is shown, and the visible light responsive member 18B can be positioned along the lane 36.

[0240] exist Fig.9A In the embodiment, the tag fragmentation entity 74 includes transposome complexes 38E and 38F, which have a visible light responsive member 18A at the 5′ end of the transferred strand 49F and the 3′ end of the non-transferred strand 44E, instead of biotin or another hydrogel-linking functional group. Therefore, when the transposome complexes 38E and 38F are introduced, the transposome complexes 38E and 38F can be selectively attached to predetermined areas 76A, 76B, 76C of the flow cell surface exposed to visible light.

[0241] like Fig.9A As shown, the tag fragmentation entity 74 is introduced into the flow channel 20. The tag fragmentation entity 74 can be introduced into a suitable liquid (water, buffer, etc.) through an inlet. In one example, the tag fragmentation entity 74 can be transported into the flow channel 20 using a pump of a sequencing instrument in which the flow cell 10 is operatively positioned.

[0242] exist Fig.9AIn the example shown, when the label fragmentation entity 74 is introduced into the flow channel 20, a specific area 76A of the circulation pool 10 is exposed to visible light. Any suitable visible light source 78 can be used to illuminate the desired areas 76A, 76B, 76C of the circulation pool 10. The visible light source 78 can be a laser, a light emitting diode, an incandescent bulb, etc. The visible light source 78 can be part of a sequencing instrument, or a separate automatic or manually operated light source. The wavelength of the emitted light is in the visible light range, i.e., about 400nm to about 700nm. The exposed visible light responsive members 18A, 18B are activated and are able to undergo a coupling reaction to attach the label fragmentation entity 74 to a portion of the recess 26 or the lane 36. Fig.9A In the present invention, transposome complexes 38E, 38F are attached asymmetrically (via their 3' and 5' ends, respectively).

[0243] The photo-responsive members 18A, 18B are not active unless they are exposed to visible light, and thus the photo-responsive members 18A, 18B present in any regions 76B, 76C of the flow cell 10 that are not exposed to visible light will not have the tag fragmentation entities 74 attached. Fig.9A In the embodiment, the visible light source 78 is not used in the regions 76B, 76C, so the light-responsive members 18A, 18B in these regions 76B, 76C are not activated. Therefore, these regions 76B, 76C can be used for samples introduced subsequently.

[0244] After coupling of the tag fragmentation entity 74 in the desired region 76A, the remaining unbound tag fragmentation entity 74 is removed from the flow channel 20 using examples of wash solutions described herein.

[0245] exist 9A to 9D In the example shown, before introducing any additional tag fragmentation entity 74 ( Fig.9D ), the attached tag fragmentation entity 74 (eg, transposome complex 38E, 38F) may undergo tag fragmentation ( Fig. 9B ) and inactivation of transposase 46 ( Fig. 9C ).

[0246] exist Fig. 9B In the embodiment of the present invention, a first DNA sample 54 is introduced into the flow channel 20. When the DNA sample 54 is present in the flow channel 20, the temperature is increased to initiate tag fragmentation. Since the transposome complexes 38E, 38F are only present in the region 76A, tag fragmentation will only occur in the region 76A. Tag fragmentation can be performed as described herein.

[0247] exist Fig. 9CIn the process, inactivation of the transposase 46 is performed. Inactivation of the transposase 46 involves removing the transposase 46 from each transposome complex 38E, 38F using any of the methods described herein (e.g., using sodium dodecyl sulfate (SDS) or a protease or another chaotropic agent, or by heating the flow cell to about 60° C.). This renders the transposome complex 38E, 38F (or other complexes that can be used as tag fragmentation entities 74) inactive for participation in the subsequently introduced DNA sample 54.

[0248] At each region / area 76A, 76B, 76C, a sequence for generating a fully adapted DNA sample fragment and a final single-stranded, fully adapted DNA sample fragment 56 ( 9A to 9D Tag fragmentation and transposase 46 inactivation are performed prior to a suitable reaction (not shown). Fig.9D The introduction of another batch of tag fragmentation entities 74 (e.g., transposome complexes 38E, 38F) is illustrated. Since the tag fragmentation entities 74 are introduced sequentially and attached only in the photoactivated regions 76A, 76B, or 76C, the tag fragmentation entities 74 in a particular batch (in this example, any complex 38 described herein) may include index sequences 51 in the transferred strands 42 and / or in the adapters 50 introduced into the flow cell. This enables standard indexing in addition to spatial indexing.

[0249] Once all desired regions 76A, 76B, 76C are attached with desired tag fragmentation entities 74, desired DNA sample 54 is tag fragmented and transposase 46 is removed, gap filling ligation or extension reaction can be used to generate fully adapted DNA sample fragments, depending on the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F. These processes can be performed as described herein, respectively.

[0250] As described above, each well 26 may be configured with primers 55, 57 for amplification and cluster generation of fully adapted DNA sample fragments 56. These processes may be performed as described herein.

[0251] If desired, forward and / or reverse fully adapted DNA sample fragments may be cleaved and subsequently denatured. If desired for a particular workflow, the cleaved and single-stranded fully adapted DNA sample fragments 56 may be transported to another area, such as on or off the flow cell 10, for enrichment as described herein.

[0252] After amplification and cluster generation, sequencing can then be performed. In one example, sequencing by synthesis is performed by introducing a sequencing primer followed by an incorporation mixture comprising labeled nucleotides. Each instance of nucleotide incorporation can be detected using optical imaging.

[0253] FIG. 10A to FIG. 10C The examples shown depict different methods in which visible light activation of the surface can be used. The flow cell 10 is divided into different areas 80, 82, 84, etc., some of which are visible light activated. In each of these figures, the tag fragmentation entity 74 is some example of the transposome complex 38A or 38B or 38C and 38D or 38E and 38F disclosed herein.

[0254] exist Fig. 10A In the example, different regions of the flow cell channel 20 include a tag fragmentation region 80, a denaturation region 82, and a clustering region 84. In this example, some or all of the recesses 26, or a portion or all of the lanes 36, can be functionalized with a visible light responsive member 18B. Any region that exhibits coupling of a tag fragmentation entity (e.g., a transposome complex 38 or primers 55, 57) can include a visible light responsive member 18B. Fig. 10A In the example shown, both the tag fragmentation region 80 and the grouping region 84 include visible light responsive members 18B.

[0255] When a transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F (which includes a visible light responsive member 18A) is to be attached in region 80, a fluid containing the desired transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F can be introduced into flow cell 10 and any light source 78 (described herein) can be used. Fig. 10A (not shown) the tag fragmentation region 80 is exposed to visible light. The visible light responsive members 18A, 18B exposed to visible light will undergo a coupling reaction to attach the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F within the recess 26 or portion of the lane 36 in the tag fragmentation region 80. The DNA sample 54 ( Fig. 10A ), for tag fragmentation and any other processes as described herein to generate fully adapted DNA fragments ( Fig. 10A not shown).

[0256] When primers 55, 57 are to be attached in region 84, a fluid containing primers 55, 57 (with visible light responsive member 18B at the 5' end) can be introduced into flow cell 10, and cluster region 84 is exposed to visible light. Visible light responsive members 18A, 18B exposed to visible light will undergo a coupling reaction to attach primers 55, 57 within a portion of recess 26 or lane 36 in cluster region 84.

[0257] It should be understood that attachment of the transposome complex 38 and attachment of the primers 55 , 57 may occur in any order, as long as attachment of the transposome complex 38 occurs prior to introduction of the DNA sample 54 .

[0258] Once the perfectly matched fragments are generated in the tag fragmentation region 80, and once the primers 55, 57 are attached in the clustering region 84, a cleavage agent can be introduced into the flow channel 20 to cleave the perfectly matched fragments. The flow can be directed to the denaturation region 82, where the perfectly matched fragments are denatured to form single-stranded perfectly matched fragments (e.g., 56), which then move to the clustering region 84, where they are seeded and amplified.

[0259] exist Fig. 10B In FIG. 8 , different regions of the flow cell channel 20 include a tag fragmentation region 80 , a denaturation region 82 , an enrichment region 86 , and a clustering region 84 .

[0260] When the transposome complex 38A or 38B or 38C and 38D or 38E and 38F (which includes the visible light responsive member 18A) is attached, a fluid containing the transposome complex 38A or 38B or 38C and 38D or 38E and 38F (which includes the visible light responsive member 18A) can be introduced into the flow cell 10 and any light source 78 (described herein) can be used. Fig. 10B (not shown) the tag fragmentation region 80 is exposed to visible light. The visible light responsive members 18A, 18B exposed to visible light will undergo a coupling reaction to attach the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F to the recess 26 or the portion of the lane 36 in the tag fragmentation region 80 ( Fig. 10B The DNA sample 54 ( Fig. 10B ), for tag fragmentation and any other processes as described herein to generate fully adapted DNA fragments ( Fig. 10B (not shown in the figure).

[0261] When probe 62' (similar to probe 62 except that visible light responsive member 18B is positioned at the end instead of biotin) is to be attached, a fluid containing probe 62' can be introduced into flow cell 10 and enrichment area 86 is exposed to visible light. Visible light responsive members 18A, 18B exposed to visible light will undergo a coupling reaction to attach probe 62' within a portion of recess 26 or lane 36 in enrichment area 86.

[0262] Once fully-matched fragments are generated in the tag fragmentation region 80 and the probe 62' is attached in the enrichment region 86, but before the primers 55, 57 are attached in the clustering region 84, a cleavage agent can be introduced into the flow channel 20 to cleave the fully-matched fragments. The flow can be directed to the denaturation region 82, where the fully-matched fragments are exposed to heat and denatured to form single-stranded fully-matched fragments (e.g., 56A, 56B, etc.), which then move to the enrichment region 86, where fragments that include the target region hybridize with the probe 62'. A wash solution can be introduced to rinse away any fragments that do not include the target region and are therefore not attached within the enrichment region 86.

[0263] When the fragment including the target region is hybridized with the probe 62', the primers 55, 57 can be introduced into the flow cell channel 20. The fluid containing the primers 55, 57 (having the visible light responsive member 18B attached to the 5' end) can be introduced into the flow cell 10, and the clustering region 84 is exposed to visible light. The visible light responsive members 18A, 18B exposed to the visible light from the light source 78 undergo a coupling reaction to attach the primers 55, 57 within the recessed portion 26 or the portion of the lane 36 in the clustering region 84.

[0264] Once the primers 55, 57 are attached, the fragments comprising the target region can be dehybridized from the probe 62' and transported to the clustering area 84 where they are seeded and amplified.

[0265] exist Fig. 10C In FIG. 8 , different regions of the flow cell channel 20 include a tag fragmentation region 80, a denaturation region 82, an amplicon hybridization and extension region 88, and a clustering region 84. Fig. 10C In the examples shown, transposome complexes 38A or 38C and 38D or 38E and 38F may be used.

[0266] When the transposome complexes 38A or 38C and 38D or 38E and 38F (which include the visible light responsive member 18A) are attached, a fluid containing the transposome complexes 38A or 38C and 38D or 38E and 38F (which include the visible light responsive member 18A) can be introduced into the flow cell 10 and any light source 78 (described herein) can be used. Fig. 10C (not shown) the tag fragmentation region 80 is exposed to visible light. The visible light responsive members 18A, 18B exposed to visible light will undergo a coupling reaction to attach the transposome complexes 38A or 38C and 38D or 38E and 38F within the recess 26 or portion of the lane 36 in the tag fragmentation region 80. The DNA sample 54 can then be introduced for tag fragmentation and any other process as described herein to generate partially adapted DNA fragments (e.g., 58, 58′).

[0267] The amplicon hybridization and extension region 88 is a region in which partially adapted DNA fragments can be hybridized and extended to introduce suitable adapters for amplification. Specific sequences 90 are introduced to the surface of the amplicon hybridization and extension region 88. These sequences 90 have a portion that can hybridize with partially adapted fragments, a portion that is a complement of the adapter to be added, and a light response member 18A at the 5' end. A fluid containing the sequence 90 can be introduced into the circulation pool 10, and the amplicon hybridization and extension region 88 can be exposed to visible light. The visible light response members 18A, 18B undergo a coupling reaction to attach the sequence 90 to a portion of the recess 26 or lane 36 in the amplicon hybridization and extension region 88.

[0268] Once partially-fit fragments are generated in the tag fragmentation region 80 and sequence 90 is attached in the amplicon hybridization and extension region 88, but before primers 55, 57 are attached in the clustering region 84, a cleaving agent can be introduced into the flow channel 20 to cleave the partially-fit fragments. The flow can be directed to the denaturation region 82, where the partially-fit fragments are heated and denatured to form single strands, which then move to the amplicon hybridization and extension region 88, where the single-stranded partially-fit fragments hybridize to the sequence 90. An extension mix can be introduced to add adapters and extend the partially-fit fragments into fully-fit fragments.

[0269] When the fully adapted fragments are hybridized to the sequence 90, the primers 55, 57 can be introduced into the flow cell channel 20. The fluid containing the primers 55, 57 (with the visible light responsive member 18A at the 5' end) can be introduced into the flow cell 10, and the clustering area 84 is exposed to visible light. The exposed visible light responsive members 18A, 18B undergo a coupling reaction to attach the primers 55, 57 within the recess 26 or the portion of the lane 36 in the clustering area 84.

[0270] Once the primers 55, 57 are attached, the fully adapted fragments can be dehybridized from the sequence 90 and transported to the clustering area 84 where they are seeded and amplified.

[0271] 9A to 9C The example shown enables at least spatial separation of DNA samples (thus using the surface as an indexing strategy), and FIG. 10A to FIG. 10C The example shown depicts a series of workflow steps that may be performed along a single flow channel 20 (eg, tag fragmentation in one region / zone, enrichment in another region / zone, etc.).

[0272] Activate the flow cell surface with a protective coating

[0273] FIG. 11A to FIG. 11D Depicted is the selective activation of flow cell surface chemistries to achieve spatial indexing. FIG. 11A to FIG. 11D The illustrated example utilizes a removable coating 92 to selectively expose the surface-bound transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F. In this example, any transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F may be used, and the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F may include biotin or another suitable linking functional group attached to the polymer hydrogel 30 or 32 present in the recess 26. For ease of illustration, the transposome complexes 38E, 38F are shown in FIG. FIG. 11A to FIG. 11D Shown in.

[0274] Flow cell 10 is similar to Figure 2A The flow cell is shown (although the base support 22 is not shown) and includes transposome complexes 38E, 38F attached to polymer hydrogels 30, 32 in recesses 26. In this example, the flow cell 10 has the same surface chemistry in each of the recesses 26. Alternatively, a Figure 2B The flow cell 10 is shown, and the transposome complexes 38E, 38F can be positioned along the lane 36. Although not shown, each flow cell recess 26 also has a primer 55, 57 attached to the polymer hydrogel 30, 32.

[0275] A removable coating 92 covers the recesses 26 (and any surface chemistry therein) and the interstitial regions 34. The removable coating 92 may be any material that melts, collapses, softens, dissolves, or permeates when exposed to a predetermined stimulus, such as light, heat, or a pH change.

[0276] The light-responsive removable coating 92 is made of a photo-cuttable material.

[0277] In some examples, the photoremovable coating is a hydrophilic polymer cross-linked with a photo-cuttable cross-linker, an acid-labile cross-linker, and / or a thermally unstable cross-linker. In a specific example, the hydrophilic polymer is a polyvinyl alcohol / polyethylene glycol graft copolymer, and the photo-cuttable cross-linker is a coumarin or o-nitrobenzyl moiety. The coumarin or o-nitrobenzyl moiety can be covalently conjugated to the poly (ethylene glycol) of the polyvinyl alcohol / polyethylene glycol graft copolymer. Coumarin or o-nitrobenzyl can be cut when exposed to ultraviolet light (UV) (100nm to 400nm) or blue light (450nm to 495nm), which results in a reduction in the cross-linking density of the coating. Therefore, when exposed, the cut polymer coating becomes hydrophilic and can be washed with an aqueous solution. In another example, the hydrophilic polymer is a polyvinyl alcohol / polyethylene glycol graft copolymer, and the photo-cuttable cross-linker is an acid-labile cross-linker. In this example, the acid-labile cross-linker is an acetal moiety. Using an acid-labile crosslinker, an acid species can be generated in the presence of a photoacid generator (PAG) and upon exposure to UV light, which changes the pH and cleaves the crosslinker, thus making the polymer coating more soluble (and easily removable by washing).

[0278] In other examples, the photoremovable coating is a hydrophilic polymer terminated with a photo-cleavable hydrophobic group or an acid-labile group. The photo-cleavable hydrophobic group or the acid-labile group is a protecting group on the polymer side chain, which makes the polymer more hydrophobic. These examples undergo a phase transition from hydrophobic to hydrophilic when exposed to light. In one example, the hydrophilic polymer is polymethacrylic acid, polyphenol, polyvinyl alcohol or polyvinyl alcohol / polyethylene glycol graft copolymer, which is functionalized with a photo-cleavable hydrophobic group (such as coumarin or o-nitrobenzyl moiety). These photo-cleavable groups are generally hydrophobic, which prevents the coating 92 from being removed and washed off by aqueous solution. When exposed to UV or visible light, these hydrophobic groups will be cut, thereby returning the removable coating 92 to its hydrophilic form. In another example, the hydrophilic polymer is polymethacrylic acid, polyphenol, polyvinyl alcohol or polyvinyl alcohol / polyethylene glycol graft copolymer, which is functionalized with an acid-labile group. Acid species can be generated in the presence of a photoacid generator (PAG) and upon exposure to UV light, which cleaves the acid-labile groups. In one example, cleavage of the tert-butyl carbonate groups produces a hydrophilic polyphenol coating that can be washed and removed by aqueous solutions.

[0279] In other examples, the photoremovable coating is a thermally responsive polymer and a photothermal additive (or photothermal filler). The thermally responsive polymer may be selected from the group consisting of: polylactic acid, poly(lactic acid-co-glycolic acid), polycaprolactone, agarose, wax, poly(acrylamide-co-acrylonitrile), poly(N-isopropylacrylamide), cyclodextrin, polyethylene glycol homopolymer, polyethylene glycol graft copolymer, polyethylene block copolymer, and combinations thereof. The photothermal additive or photothermal filler included in the composite material may be a nanoscale or any micron-scale structure that absorbs light (e.g., photons) energy within a certain wavelength range and converts the absorbed energy into heat. The photothermal filler (or photothermal additive) may be selected from the group consisting of: gold nanoparticles, silver nanoparticles, iron oxide nanoparticles, polypyrrole particles, graphene sheets, carbon nanotubes, carbon nanodots, black phosphorus particles, azobenzene particles, and combinations thereof. Upon exposure to UV or visible light, the energy absorbed by the photothermal additive is converted into heat, which induces a phase change in the polymer matrix (due to the presence of the thermally responsive polymer). This phase change causes the photoremovable coating to soften or dissolve. The softened or dissolved coating can then be removed using an aqueous solvent.

[0280] Still other photoremovable coatings are light and pH responsive. With these coatings, exposure to light induces proton release. Examples of these photoremovable coatings include 2-naphthol-6,8-disulfonic acid or 1,2-naphthoquinone-2-diazide-5-sulfonic acid.

[0281] The heat-removable coating is made of a thermally responsive material. For example, the thermally responsive material may be a polymer, wax, or myristic acid that melts when a certain temperature is reached. As another example, the thermally responsive material may be a polymer that changes from a hydrophobic state to a hydrophilic state when a certain temperature is reached, such as a UCST (upper critical solution temperature) polymer, such as poly(acrylamide-co-acrylonitrile). As yet another example, the thermally responsive material may be a polymer that changes from a hydrophilic state to a hydrophobic state when a certain temperature is reached, such as a LCST (lower critical solution temperature) polymer, such as poly(N-isopropylacrylamide) or PNIPAAm, which has a transition temperature of about 32°C to 44°C. In a specific example, the thermally removable coating may include a polymer selected from the group consisting of: polylactic acid, poly(lactic acid-co-glycolic acid), polycaprolactone, agarose, wax, poly(acrylamide-co-acrylonitrile), poly(N-isopropylacrylamide), cyclodextrin, polyethylene glycol homopolymer, polyethylene glycol graft copolymer, polyethylene block copolymer, and combinations thereof. Another suitable thermoresponsive material is composed of a hydrophilic polymer cross-linked with a thermally unstable cross-linking agent. The example of a thermally unstable cross-linking agent is disuccinimidyl adipate (DSA). DSA is a homobifunctional cross-linking agent with two NHS ester groups. NHS esters react with primary amines to form stable amide bonds. DSA reacts with primary amines, thereby producing covalent bonds through the formation of amide bonds. DSA contains a joint that is easily hydrolyzed at elevated temperatures. As another example, the thermoresponsive material can be a gel, such as hydroxypropyl methylcellulose, which has a viscosity that is temperature dependent.

[0282] The pH-variable removable coating is made of or includes a pH-responsive material. Alternatively, the pH-responsive material may be adjacent to the removable coating. Examples of polymers soluble in aqueous solutions having different pH levels include chitosan, which is soluble under acidic conditions, and copolymers of water-insoluble monomers and amine-functional monomers, which copolymers can be adjusted to dissolve at different pH levels depending on the content of the amino-functional monomer. An example of a copolymer is dimethylaminoethyl methacrylate, which is soluble under alkaline conditions. Other examples of pH-responsive polymers are sold under the trade name Those polymers are commercially available from Evonik. As described herein, light and / or heat can be used to generate localized pH changes.

[0283] FIG. 11A to FIG. 11D The method shown involves introducing a DNA sample 54 into a flow cell 10 ( Fig.11A ); by removing a portion of the removable coating 92 from the predetermined areas 76A, 76B, 76C of the flow cell 10, a subset of the transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F are exposed at the predetermined areas 76A, 76B, 76C ( Fig. 11B) ; and initiating tag fragmentation of at least a portion of the DNA sample 54 at predetermined regions 76A, 76B, 76C (FIG. 10B).

[0284] exist Fig.11A In the embodiment of the present invention, the first DNA sample 54 is introduced into the flow channel 20. The first DNA sample 54 can be introduced into a suitable liquid (water, buffer, etc.) introduced through the opening (inlet, outlet) so that it flows in a desired direction. In one example, the first DNA sample 54 can be transported into the flow channel 20 using a pump of a sequencing instrument in which the flow cell 10 is operatively positioned. Since the removable coating 92 covers the transposome complexes 38E, 38F, the DNA sample 54 cannot bind anywhere.

[0285] When the DNA sample 54 is present in the flow channel 20, the predetermined area 76A of the flow cell 10 is exposed to a stimulus that causes the removable coating 92 to melt, dissolve, or permeate. Fig. 11B As described herein, removable coating 92 may be sensitive to light, heat, or pH changes.

[0286] When light is the stimulus, any suitable visible light source 78 may be used to illuminate the desired regions / areas 76A, 76B, 76C of the flow cell 10. Fig. 11B and Fig.11D A light source 78 is shown in FIG, but it will be appreciated that this could be replaced by a heating mechanism.

[0287] When heat is the stimulus, any suitable heating mechanism may be used. The heating mechanism may be included in a complementary metal oxide semiconductor chip coupled to the flow cell substrates 12, 14, included as part of the cover of the flow cell 10, or included / embedded in the flow cell substrates 12, 14, or deposited within the recess 26. Examples of heating mechanisms may include one or more electrode materials that are capable of converting electricity into a suitable amount of thermal energy to heat the desired portion of the removable coating 92. In other examples, an external heating mechanism may be used, such as a heater of a sequencing instrument in which the flow cell 10 is positioned.

[0288] In some cases, when heat is the removal mechanism, other regions 76B, 76C of the flow channel 20 may be actively cooled while region 76A is heated. Localized cooling may be performed with an active cooling system of an external heater (e.g., Peltier). It should be understood that while localized cooling may be used, it may not be used when heating is limited to the desired region 76A. In other words, a heating mechanism may be used to locally heat the region where the coating 92 is to be removed, and other regions may remain unheated.

[0289] When pH change is stimulation, pH change can be initiated by changing the temperature of predetermined area 76A, 76B, 76C. In some examples, pH level decreases with increasing temperature, and therefore heating mechanism can be used to induce local changes in pH. In one example, a buffer that reduces pH with increasing temperature, such as acetate buffer, citrate buffer or phosphate buffer, can be added to circulation pool 10 before local heating. In another example, a buffer that increases pH with increasing temperature, such as borate buffer, can be added to circulation pool 10 before local heating. In still another example, a buffer that can increase or reduce pH with increasing temperature, such as glycine buffer, can be added to circulation pool 10 before local heating. In other examples, an acid (or another source of H+ ions that reduce pH) can be generated near an electrode adjacent to predetermined area 76A (e.g., in a cover, substrate 12, 14, etc.), and the source of acid or H+ ions that reduce pH reduces pH. In still other examples, when predetermined area 76A is exposed to light, an acid (or another source of H+ ions that reduce pH) can be generated. Light exposure induces a photocatalytic reaction and thus releases protons in the desired area for coating removal. Thus, pH changes are combined with temperature changes or light exposure, which enables spatial control.

[0290] Exposing a portion of the removable coating 92 to a stimulus causes the portion of the removable coating 92 located at the predetermined region 76A to melt, dissolve or permeate. The removal of the portion of the removable coating 92 exposes the transposome complexes 38E, 38F at the region / zone 76A. This allows the DNA sample 54 to bind at these transposome complexes 38E, 38F. Tag fragmentation can then be initiated in the region / zone 76A. Tag fragmentation can be performed as described herein.

[0291] Following tag fragmentation in the desired region 76A, the flow channel 20 may be washed using examples of wash solutions described herein to remove melted, dissolved, or infiltrated portions of the removable coating 92 and the tag fragmentation reagent.

[0292] exist Fig. 11C , removal of the transposase 46 is performed. The transposase 46 from each transposome complex 38E, 38F can be removed using any of the methods described herein (e.g., using sodium dodecyl sulfate (SDS) or a protease or another chaotropic agent, or by heating the flow cell to about 60° C.). This makes the transposome complex 38E, 38F available for subsequent introduction of a DNA sample (e.g., Fig.11D The second DNA sample 54B) is inactive.

[0293] The process of adding a DNA sample 54, triggering local removal of the removable coating 92 in another predetermined region (e.g., 76B or 76C), tag fragmentation, and removal of the transposase 46 can then be repeated for as many DNA samples 54 and regions as needed and / or possible within a given flow channel 20. This will allow for tag fragmentation of multiple DNA samples 54, 54B in corresponding regions 76A, 76B, etc., which will continue through clustering. The addition of a second DNA sample 54B, the removal of a second portion of the removable coating 92 in the predetermined region 76B, and the tag fragmentation of the second DNA sample 54B are shown in FIG. Fig.11D middle.

[0294] After performing appropriate reactions to generate fully matched DNA sample fragments ( FIG. 11A to FIG. 11D Once all desired regions / regions 76A, 76B, 76C have caused the desired DNA sample 54 to be fragmented by tags and the transposase 46 to be removed, a gap-filling ligation or extension reaction can be used to generate fully adapted DNA sample fragments, depending on the transpososome complex 38A, or 38B, or 38C and 38D, or 38E and 38F used. These processes can be performed as described herein, respectively.

[0295] As described above, each recess 26 can be configured with primers 55, 57 for amplification and cluster generation. Amplification and cluster generation can be performed as described herein. Cutting of the DNA sample fragments that are fully adapted in the forward or reverse direction can then be performed. Denaturation will release the cut fragments, leaving other (e.g., reverse or forward) single-stranded fully adapted fragments (e.g., 56A, 56B, etc.) attached to the flow cell surface.

[0296] Sequencing can then be performed. In one example, sequencing by synthesis is performed by introducing a sequencing primer followed by an incorporation mixture comprising labeled nucleotides. Each instance of nucleotide incorporation can be detected using optical imaging.

[0297] Activation of the flow cell surface with encapsulated tag fragmentation entities

[0298] FIG. 12A to FIG. 12D The selective release of tag fragmentation entities 74 to achieve spatial indexing is depicted. FIG. 12A to FIG. 12DThe example shown utilizes an encapsulated complex 94 to selectively expose the surface-bound transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F to an activating chemical. In this example, any transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F may be used, and the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F may include biotin or another suitable linking functional group attached to the polymer hydrogel 30 or 32 present in the recess 26. For ease of illustration, the transposome complex 38E, 38F is shown in FIG. FIG. 12A to FIG. 12D Shown in.

[0299] Flow cell 10 is similar to Figure 2A The flow cell is shown (although the base support 22 is not shown) and includes transposome complexes 38E, 38F attached to the polymer hydrogels 30, 32 in the recesses 26. In this example, the flow cell 10 has the same surface chemistry (e.g., transposome complexes 38E, 38F) in each of the recesses 26. Alternatively, a flow cell may be used. Figure 2B The flow cell 10 is shown, and the transposome complexes 38E, 38F can be positioned along the lane 36. Although not shown, each flow cell recess 26 also has a primer 55, 57 attached to the polymer hydrogel 30, 32.

[0300] The encapsulated composite includes an example of a tag fragmentation entity 74 surrounded by a coating material 98. In this example, the tag fragmentation entity 74 is a catalytic metal ion 96, such as Mg, which catalyzes the tag fragmentation. 2+ , Mn 2+ wait.

[0301] The coating material 98 is removable when exposed to a release mechanism / stimulus such as temperature, light, or pH. Any temperature, light, or pH responsive material described herein for the removable coating 92 can be used for the coating material 98. Fig. 12A and Fig.12D A light source 78 is shown in FIG, but it will be appreciated that this could be replaced by a heating mechanism.

[0302] Another example of a temperature-responsive coating material is a temperature-sensitive wax or fatty acid; and triggering the release of the catalytic metal ions 96 involves heating the predetermined area 76A, 76B, 76C to above the melting temperature of the temperature-sensitive wax. Some examples of suitable temperature-sensitive waxes include myristic acid, palmitic acid, paraffin, refined wax, or soy wax, each of which melts at a temperature in the range of about 40°C to about 50°C. Other examples of suitable temperature-sensitive waxes include stearic acid, beeswax, microcrystalline polyethylene wax, or carnauba wax, each of which melts at a temperature in the range of about 60°C to about 80°C. In these examples, the predetermined area 76A, 76B, 76C is heated to a desired temperature to melt the wax and release the catalytic metal ions 96. Still another example of a temperature-responsive coating material is a temperature-sensitive polymer; and triggering the release of the catalytic metal ions 96 involves heating the flow cell 10 to above the melting temperature of the temperature-sensitive polymer. Examples of suitable temperature-sensitive polymers include UCST polymers, i.e., poly(acrylamide-co-acrylonitrile), hydroxypropylmethylcellulose, agarose, or gelatin, each of which dissolves at temperatures above 30° C. Other examples of suitable temperature-sensitive polymers include LCST polymers, i.e., poly(N-isopropylacrylamide), methylcellulose, or poloxamer, each of which dissolves at temperatures below 30° C. In these examples, the predetermined regions 76A, 76B, 76C are heated to a desired temperature to dissolve the polymer and release the catalytic metal ions 96.

[0303] Some specific examples of suitable pH sensitive polymers for coating materials include L100 (methacrylic acid copolymer type B from Evonik, Inc.) or MAE-100 (methacrylic acid copolymer type A, from BASF Corp.), each of which is soluble at a pH greater than 6. Other examples of suitable pH-sensitive polymers include RL / RS100 (methacrylic acid copolymer, from Evonik) or carboxymethyl cellulose, each of which is soluble at a pH greater than 8. Other examples of suitable pH-sensitive polymers include E (aminodimethyl methacrylate copolymer from Evonik, Inc.) or chitosan, each of which is soluble at a pH less than 3. In these examples, the pH of the predetermined regions 76A, 76B, 76C is adjusted to a pH below the pH to which the polymer is sensitive (e.g., if the solubility is pH X or lower) or above the pH to which the polymer is sensitive (e.g., if the solubility is pH X or higher), and the polymer dissolves. The dissolution of the polymer releases the catalytic metal ions 96.

[0304] The encapsulated composite 94 can be formed by generating a dispersion of the coating material 98, spraying the dispersion onto the catalytic metal ions 96 in a fluidized bed, and drying the composite. Alternative forms of drying can be used, such as freeze drying, vacuum drying, or microwave assisted drying. The dried product can then be powdered into small matrix particles containing a mixture of the trigger material and the catalytic metal. Other suitable coating techniques can be used, such as pan coating, spray drying, etc., which effectively form a film of the coating material 98 on the catalytic metal ions 96.

[0305] FIG. 12A to FIG. 12D The method shown involves introducing a DNA sample 54 into a flow cell 10, whereby the DNA sample 54 binds to the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F across the flow cell 10; introducing an encapsulated complex 94 into the flow cell 10, the encapsulated complex 94 including a catalytic metal ion 96 surrounded by a coating material 98; and selectively releasing the catalytic metal ion 96 from the encapsulated complex 94 at a predetermined region 76A of the flow cell 10 by exposing the encapsulated complex to a mechanism that initiates removal of the coating material 98, thereby initiating tag fragmentation of a portion of the DNA sample 54 in the predetermined region 76A, while leaving another portion of the DNA sample 54 unfragmented by the tag in another region 76B, 76C.

[0306] exist Fig. 12A In the example, the first DNA sample 54 is introduced into the flow channel 20. The first DNA sample 54 can be introduced into a suitable liquid (water, buffer, etc.) through the inlet. In one example, the first DNA sample 54 can be transported into the flow channel 20 using a pump of a sequencing instrument in which the flow cell 10 is operatively positioned. The DNA sample 54 can bind to the transposome complex 38E, 38F in each of the predetermined regions 76A, 76B, 76C, but tag fragmentation does not occur in each of the predetermined regions 76A, 76B, 76C.

[0307] When the DNA sample 54 is present in the flow channel 20, the predetermined area 76A of the flow cell 10 is exposed to a stimulus that causes the coating material 98 to melt, dissolve, or permeate. The removal of the coating material 98 from the encapsulated complex 94 releases the catalytic material 96 in the predetermined area 76A. Fig. 12AAs described herein, the coating material 98 may be sensitive to light, heat, or pH changes. These stimuli may be applied as described herein for the removable coating 92. When the coating material 98 is removed, the release of the catalytic metal ions 96 is localized so that it catalyzes the tag fragmentation in the predetermined area 76A, but does not catalyze the tag fragmentation in the other areas 76B, 76C. The tag fragmentation may be performed as described herein. When heat is the triggering factor, the other areas 76B, 76C may be cooled to prevent the catalytic metal ions 96 from being released prematurely.

[0308] Following tag fragmentation in the desired region 76A, the flow channel 20 may be washed using examples of wash solutions described herein to remove melted, dissolved, or infiltrated portions of the coating material 98 and the tag fragmentation reagents.

[0309] exist Fig. 12B , removal of the transposase 46 is performed. The transposase 46 from each transposome complex 38E, 38F can be removed using any of the methods described herein (e.g., using sodium dodecyl sulfate (SDS) or a protease or another chaotropic agent, or by heating the flow cell to about 60° C.). This process releases the bound but untagged fragmented DNA sample 54 from the inactive transposome complexes 38E, 38F in regions 76B and 76C. The tagged fragmented fragments 58, 58′ remain attached in region 76A because they have been linked to the corresponding 3′ ends of the transferred strands 42E, 42F. The released transposase 46 and untagged fragmented DNA sample 54 can be removed from the flow cell 10.

[0310] The exemplary method then involves reintroducing the transposase 46. Fig. 12C . Transposase 46 binds to transposon ends 40E, 40F to reform transposome complexes 38E, 38F. This makes transposome complexes 38E, 38F in regions 76B, 76C ready to participate in a subsequently introduced DNA sample, e.g. Fig.12D The second DNA sample 54B.

[0311] The process of adding a DNA sample 54, triggering local release of the catalytic metal 96 in another predetermined region (e.g., 76B or 76C), tag fragmentation, removal of the transposase 46, the catalytic metal ions 96, and the bound but un-tagged fragmented DNA sample 54, and reintroduction of the transposase 46 can then be repeated for as many DNA samples 54 and regions as needed and / or possible within a given flow channel 20. This will allow for tag fragmentation of multiple DNA samples 54, 54B in corresponding regions 76A, 76B, etc., which will continue through clustering. The addition of a second DNA sample 54B, the local release of the catalytic metal 96 in the predetermined region 76B, and the tag fragmentation of the second DNA sample 54B are shown in FIG. Fig.12D middle.

[0312] After performing appropriate reactions to generate fully matched DNA sample fragments ( FIG. 12A to FIG. 12D Once all desired regions / regions 76A, 76B, 76C have caused the desired DNA sample 54 to be fragmented by tags and the transposase 46 has been removed for the last time, a gap-filling ligation or extension reaction can be used to generate fully adapted DNA sample fragments, depending on the transpososome complex 38A, or 38B, or 38C and 38D, or 38E and 38F used. These processes can be performed as described herein, respectively.

[0313] As described above, each recess 26 can be configured with primers 55, 57 for amplification and cluster generation. Amplification and cluster generation can be performed as described herein. Cutting of the DNA sample fragments that are fully adapted in the forward or reverse direction can then be performed. Denaturation will release the cut fragments, leaving other (e.g., reverse or forward) single-stranded fully adapted fragments (e.g., 56A, 56B, etc.) attached to the flow cell surface.

[0314] Sequencing can then be performed. In one example, sequencing by synthesis is performed by introducing a sequencing primer followed by an incorporation mixture comprising labeled nucleotides. Each instance of nucleotide incorporation can be detected using optical imaging.

[0315] Heat activated flow cell surface

[0316] FIG. 13A to FIG. 13D Depicted is the selective activation of surface-bound tag fragmentation entities 74 to achieve spatial indexing. FIG. 13A to FIG. 13DThe example shown utilizes heat to selectively activate the surface-bound transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F. In this example, any transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F may be used, and the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F may include biotin or another suitable linking functional group attached to the polymer hydrogel 30 or 32 present in the recess 26. For ease of illustration, the transposome complexes 38E, 38F are shown in FIG. FIG. 13A to FIG. 13D Shown in.

[0317] Flow cell 10 is similar to Figure 2A The flow cell is shown (although the base support 22 is not shown) and includes transposome complexes 38E, 38F attached to the polymer hydrogels 30, 32 in the recesses 26. In this example, the flow cell 10 has the same surface chemistry (e.g., transposome complexes 38E, 38F) in each of the recesses 26. Alternatively, a flow cell may be used. Figure 2B The flow cell 10 is shown, and the transposome complexes 38E, 38F can be positioned along the lane 36. Although not shown, each flow cell recess 26 also has a primer 55, 57 attached to the polymer hydrogel 30, 32.

[0318] FIG. 13A to FIG. 13D The method shown involves selectively activating a subset of the transposome complexes 38E, 38F in a predetermined region 76A, 76B, 76C of the flow cell 10 by heating the predetermined region 76A to an activation temperature and cooling the other regions 76B, 76C to below the activation temperature; and introducing a DNA sample 54 into the flow cell 10, whereby a portion of the DNA sample 54 binds to the subset of the transposome complexes 38E, 38F in the predetermined region 76A and is fragmented by its tags, and another portion of the DNA sample 54 binds to the transposome complexes 38E, 38F in the other regions 76B, 76C and remains unfragmented by its tags.

[0319] exist Fig.13A In the embodiment, the region 76A of the flow cell 10 to initiate tag fragmentation is exposed to the activation temperature of the transposome complexes 38E, 38F. In one example, the activation temperature is in the range of about 20° C. to about 55° C. Local heating can be accomplished using any heating mechanism described herein.

[0320] When local heating is performed, local cooling can also be performed in other areas 76B, 76C where tag fragmentation is not initiated. In one example, the cooling temperature is 18°C ​​or lower. Local cooling can be accomplished using any cooling mechanism described herein. Cooling to a lower temperature helps inhibit activation of the transposome complex 38E, 38F and prevents tag fragmentation from occurring in areas 76B, 76C where tag fragmentation is not desired.

[0321] Once the desired region 76A is heated and the other regions 76B, 76C are cooled (if necessary), the first DNA sample 54 is introduced into the flow channel 20. The first DNA sample 54 can be introduced into a suitable liquid (water, buffer, etc.) through the inlet. In one example, the first DNA sample 54 can be transported into the flow channel 20 using a pump of a sequencing instrument in which the flow cell 10 is operatively positioned. The DNA sample 54 can bind to the transposome complex 38E, 38F in each of the predetermined regions 76A, 76B, 76C, but tag fragmentation only occurs in the heated regions, e.g. Fig.13A The region 76A in which the transposome complexes 38E and 38F have been activated. Tag fragmentation can be performed as described herein.

[0322] Following tag fragmentation in the desired region 76A, the flow channel 20 may be washed using examples of wash solutions described herein to remove the tag fragmentation reagents.

[0323] Figures 13A to 13D The method shown then also includes removing the transposase 46 of each of the transposome complexes 38E, 38F, thereby releasing the other portion of the DNA sample 54, and thereby that portion of the DNA sample (e.g., the labeled fragments 58, 58′) remains attached in the predetermined area 76A; washing the removed transposase 46 and the released DNA sample 54 from the flow cell 10; and introducing fresh transposase 46 into the flow cell 10, thereby reforming the transposome complexes 38E, 38F in the other area 76B or 76C.

[0324] exist Fig. 13B, transposase removal is performed. The transposase 46 from each transposome complex 38E, 38F can be removed using any of the methods described herein (e.g., using sodium dodecyl sulfate (SDS) or a protease or another chaotropic agent, or by heating the circulation cell to about 60°C). This process releases the bound but untagged fragmented DNA sample 54 from the inactive transposome complexes 38E, 38F in the cooling regions 76B and 76C. The tagged fragmented fragments 58, 58' remain attached in the heating region 76A because they have been connected to the corresponding 3' ends of the transferred strands 42E, 42F. The released transposase 46 and untagged fragmented DNA sample 54 can be removed from the circulation cell 10 using a washing solution.

[0325] As mentioned, the exemplary method then involves reintroducing the transposase 46. Fig. 13C . Transposase 46 binds to transposon ends 40E, 40F to reform transposome complexes 38E, 38F. This makes transposome complexes 38E, 38F in regions 76B, 76C ready to participate in a subsequently introduced DNA sample, e.g. Fig.13D The second DNA sample 54B.

[0326] The process of localized heating and cooling, addition of DNA sample 54, removal of transposase 46 and bound but un-tagged fragmented DNA sample 54, and reintroduction of transposase 46 can then be repeated for as many DNA samples 54 and regions as desired and / or possible within a given flow channel 20. This will allow for tag fragmentation of multiple DNA samples 54, 54B in corresponding regions 76A, 76B, etc., which will continue through clustering. The addition of a second DNA sample 54B and localized heating in Fig.13D Shown in.

[0327] After performing appropriate reactions to generate fully matched DNA sample fragments ( FIG. 13A to FIG. 13D Once all desired regions / regions 76A, 76B, 76C have caused the desired DNA sample 54 to be fragmented by tags and the transposase 46 has been removed for the last time, a gap-filling ligation or extension reaction can be used to generate fully adapted DNA sample fragments, depending on the transpososome complex 38A, or 38B, or 38C and 38D, or 38E and 38F used. These processes can be performed as described herein, respectively.

[0328] As described above, each recess 26 can be configured with primers 55, 57 for amplification and cluster generation. Amplification and cluster generation can be performed as described herein. Cutting of the DNA sample fragments that are fully adapted in the forward or reverse direction can then be performed. Denaturation will release the cut fragments, leaving other (e.g., reverse or forward) single-stranded fully adapted fragments (e.g., 56A, 56B, etc.) attached to the flow cell surface.

[0329] Sequencing can then be performed. In one example, sequencing by synthesis is performed by introducing a sequencing primer followed by an incorporation mixture comprising labeled nucleotides. Each instance of nucleotide incorporation can be detected using optical imaging.

[0330] Selective capture of DNA samples

[0331] Fig.15A The top view partially depicts different regions / areas 76A, 76B, 76C, 76D, 76E, 76F of the lane 36 of the flow cell 10. Fig. 15B As shown, each region / zone 76A, 76B, 76C, 76D, 76E and 76F includes a different type of target primer 100A, 100B, 100C, 100D, 100E, 100F that is at least capable of spatial indexing.

[0332] Flow cell lane 36 is similar to Figure 2A , and may be the only lane of the flow cell 10, or may be one of the multiple lanes 36 of the flow cell 10. In short, the flow cell lane 36 is formed in the multilayer substrate 12 and includes a recessed portion 26 defined in the patterned layer 24. Each recessed portion 26 includes a polymer hydrogel 32 therein and a set of amplification primers (i.e., primers 55 and 57) attached to the polymer hydrogel 30 or 32. Alternatively, a Figure 2B Flow cell lane 36 is shown, and primers 55 and 57 can be attached to polymer hydrogel 30 or 32 along lane 36.

[0333] In these examples, the flow cell lane 36 is divided into at least two regions / areas 76A, 76B. The number of regions / areas 76A, 76B depends on the number of different samples to be introduced into the flow cell lane 36. The number of regions / areas 76A, 76B is also limited by the size of the lane 36.

[0334] Regions / zones 76A, 76B, 76C, 76D, 76E, 76F are defined by specific types of target primers, see Fig. 15B100A, 100B, 100C, 100D, 100E, 100F in the reference numerals 100A, 100B, 100C, 100D, 100E, 100F in the target primers are attached to the polymer hydrogel 30 or 32 in the region / zone 76A, 76B, etc. As used herein, the reference numeral 100 refers collectively to all target primers, while the reference numerals 100A, 100B, 100C, 100D, 100E, 100F specifically refer to those target primers in the corresponding regions / zones 76A, 76B, 76C, 76D, 76E, 76F. Similarly, the reference numeral 102 refers collectively to all spatial tags, while the reference numerals 102A, 102B, 102C, 102D, 102E, 102F specifically refer to the spatial tags complementary to the corresponding target primers 100A, 100B, 100C, 100D, 100E, 100F.

[0335] Each target primer 100 in a given region 76A, 76B, 76C, 76D, 76E, or 76F of the flow cell 10 has the same sequence as each other target primer 100 in that region 76A, 76B, 76C, 76D, 76E, or 76F, and the sequence is complementary to the sequence of the spatial tag 102 to be hybridized therewith. A target primer 100D in one region 76D is orthogonal to target primers 100A, 100B, 100C, 100E, and 100F in each of the other regions 76A, 76B, 76C, 76E, and 76F. When the term "orthogonal" is used to describe the target primer 100, it means that the target primer 100D in one region 76D has a different oligonucleotide sequence from the target primers 100A, 100B, 100C, 100E and 100F in each of the other regions 76A, 76B, 76C, 76E and 76F, and therefore the target primers 102A, 102B, 102C, 102D, 102E, 102F in the corresponding regions 76A, 76B, 76C, 76D, 76E, 76F are able to hybridize only with the corresponding complementary spatial tags 102A, 102B, 102C, 102D, 102E, 102F.

[0336] The 5' end of the target primer 100 includes a functional group that attaches it to the polymer hydrogel 30 or 32. In the method using the inactive component (see Fig.16A and Fig. 16B104 and 106 in the target primers 100), it may not be desirable to use a biotinylated polymer hydrogel 30 because the passivating component may include biotin as its attachment molecule. In other cases, when a biotinylated polymer 30 is used, the 5′ end of each of the target primers 100 is biotin, and avidin or streptavidin 60 can be used to attach the target primers 100A, 100B, etc. in the desired regions 76A, 76B, etc. When a polymer hydrogel 32 is used, the 5′ end of each of the target primers 100 can be any suitable functional group that can be covalently attached to the RA group of the polymer hydrogel 32.

[0337] Different groups of target primers 100A, 100B, etc. can be sequentially distributed in regions / areas 76A, 76B, etc. using a high-precision coating method. In one example, high-precision coating is achieved using a precision gantry tool. In other examples, a stripe coating or patch coating with a slot die coating tool is used to perform a high-precision coating method. The high-precision coating method can also be used with other coating methods, such as spraying or jetting, for example, by inkjet. In one example, a first group of target primers 100A can be distributed at region 76A and allowed to incubate so that they are grafted onto the polymer hydrogel 30 or 32. When biotin-avidin / streptavidin-biotin is used for connection, avidin / streptavidin 60 can be attached or introduced according to any example described herein.

[0338] include Fig.15A 15 can be part of a kit. The kit includes at least two fluids, each fluid is specifically designed for use with target primers 100A, 100B, etc. in one of the regions 76A, 76B, etc. The number of fluids in the kit corresponds to the number of regions 76A, 76B, etc. defined in the lane 36. For example, a kit including a flow cell 10 having the lane 36 shown in FIG. 15 would include six different fluids, one for each of the regions 76A, 76B, 76C, 76D, 76E, 76F.

[0339] Each fluid in the kit includes a liquid carrier and a first plurality of transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F dispersed in the liquid carrier, wherein each of the transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F includes a spatial tag 102 complementary to a target primer 100 attached to one of regions 76A, 76B, 76C, 76D, 76E, or 76F. For example, the fluid used with region 76D includes transposome complexes 38E and 38F, the transposome complexes including a spatial tag 102D, the sequence of which is complementary to the target primer 100D. As a specific example, the spatial tag 10D may be attached to the 3′ end of the non-transferred strand (e.g., at Fig.14D 48E in ) and the 5′ end of the transferred strand (at Fig.14D 48F in the flow cell 10), so that these complexes 38E, 38F directly hybridize with the target primer 100D. In one example, the flow cell 10 has two regions 76A, 76B defined in the swimming lane 36, and the kit includes: a first fluid, the first fluid including a first liquid carrier; and a first plurality of transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F dispersed in the first liquid carrier, each of the first plurality of transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F including a first spatial tag 102A attached to the first region 76A located in the flow cell 10. 6A; and a second fluid comprising a second liquid carrier; and a second plurality of transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F dispersed in the second liquid carrier, each of the second plurality of transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F comprising a second spatial tag 102B that is complementary to the target primer 100B attached to the recess 26 located at the second area 76B of the circulation pool 10.

[0340] The liquid carrier of the corresponding fluid can be water. Buffers and / or salts can be added to the liquid carrier. The pH range of the buffer is 5 to 12. Examples of neutral buffers include tris (hydroxymethyl) aminomethane (Tris or TRIS) buffers, such as Tris-HCl or Tris-EDTA, or carbonate buffers (e.g., 0.25M to 1M). Sodium sulfate (e.g., 1M to 2M) is a suitable salt that can be used. Transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F can also be included in the liquid carrier at a concentration ranging from about 0.1 μM to about 1 μM.

[0341] As mentioned, any transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F described herein may be used. In this example, each of the transposome complexes 38A, or 38B, or 38C and 38D, or 38E and 38F further comprises one of the spatial tags 102A, 102B, 102C, 102D, 102E, or 102F. The spatial tag 102 is an oligonucleotide primer complementary to the target primer 100 contained within the region 76A, 76B, etc. of the flow cell 10 with which the fluid (containing the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F and the spatial tag 102) is to be used. Therefore, the spatial tags 102A, 102B, etc. used in each fluid will depend on the corresponding region 76A, 76B, etc. and the target primers 100A, 100B, etc. in that region 76A, 76B, etc.

[0342] When using transposome complex 38A ( Fig.14A ) or transposome complex 38B ( Fig. 14B ), the spatial tag 102 is covalently or non-covalently attached to the 5′ end of the transferred strand 42. When the transposome complexes 38C and 38D are used ( Fig. 14C ), the spatial tag 102 is covalently or non-covalently attached to the 5′ end of each of the transferred strands 42C and 42D of the complexes 38C and 38D, respectively. When the transposome complexes 38E and 38F are used ( Fig.14D ), the spatial tag 102 is attached to the 3′ end of the non-transferred strand 44E of the complex 38E and the 5′ end of the transferred strand 42F of the complex 38F. Fig. 15B In the example shown, the spatial tags 102A, 102B, 102C, 102D, 102E, 102F are attached to the transposome complexes 38E and 38F by a biotin-avidin / streptavidin-biotin interaction, wherein the terminal groups 48E, 48F are both biotin, the 5′ end of the spatial tag 102 is biotin, and the avidin / streptavidin 60′ is attached to the biotin. Alternatively, the spatial tags 102A, 102B, 102C, 102D, 102E, 102F are attached to the transposome complexes 38E and 38F by a biotin-avidin / streptavidin interaction, wherein the terminal groups 48E, 48F are both biotin, and the avidin / streptavidin 60′ is covalently attached to a thiol-modified oligonucleotide at the 5′ end of the spatial tag 102.

[0343] For preparation Fig.15A and Fig. 15BAn example method for lane 36 shown in the flow cell includes attaching a set of amplification primers (e.g., primers 55, 57) along the flow cell lane 36 (e.g., attached to a polymer hydrogel 30 or 32 in the lane 36 or in the recess 26); and sequentially attaching orthogonal target primers 100 (e.g., 100A, 100B, etc.) in at least two different regions 76A, 76B, etc. of the flow cell lane 36.

[0344] We will now describe the use Fig.15A and Fig. 15B Two exemplary methods of sequencing a flow cell lane 36. At the beginning of each method, a flow cell 10 having regions 76A, 76B, etc. defined in a lane 36 is operatively positioned within a sequencing instrument.

[0345] An exemplary method includes: i) generating fully adapted first DNA sample fragments in the first region 76A of the flow cell 10 by: introducing a first fluid (including a first plurality of transposome complexes 38A or 38B, etc.) into the flow cell 10 at a hybridization temperature, whereby first spatial tags 102A are respectively hybridized with target primers 100A attached to the recesses 26 located at the first region 76A of the flow cell 10; introducing a first DNA sample 54 into the flow cell 10, whereby the first DNA sample 54 is fragmented by the tags of the first plurality of transposome complexes 38A or 38B, etc.; removing the transposase 46 of each transposome complex in the first plurality of transposome complexes 38A or 38B, etc.; and performing ii) generating fully matched second DNA sample fragments in the second region 76B of the flow cell 10 by: introducing a second fluid into the flow cell 10 at a hybridization temperature, whereby the second spatial tags 102B respectively hybridize with the target primers 100B attached to the recessed portion 26 located at the second region 76B of the flow cell 10; introducing a second DNA sample 54B into the flow cell 10, whereby the second DNA sample 54B is fragmented by tags such as a second plurality of transposome complexes 38A or 38B; removing the transposase 46 of each transposome complex in the second plurality of transposome complexes 38A or 38B; and performing a gap-filling ligation or extension reaction.

[0346] At the beginning of the exemplary method, a first fluid (including a first plurality of transposome complexes 38A or 38B, etc., having a first spatial marker 102A) is introduced into a flow cell lane 36. The first fluid can be introduced through an inlet. In one example, the first fluid can be transported into the lane 36 using a pump of a sequencing instrument.

[0347] The temperature of the flow cell lane 36 is at or reaches the hybridization temperature, so that the first spatial tag 102A hybridizes with the complementary target primer 100A located in the first region 76A, respectively. Since the target primers 100B, 100C, 100D, 100E, and 100F located in the other regions 76B, 76C, 76D, 76E, and 76F are not complementary to the first spatial tag 100A, the first plurality of transposome complexes 38A or 38B, etc. will not bind in these regions 76B, 76C, 76D, 76E, and 76F.

[0348] The first DNA sample 54 is then introduced into the flow cell lane 36 as described herein (e.g., with a tag fragmentation buffer). Since the first plurality of transposome complexes 38A or 38B, etc. is the only set of transposome complexes 38A or 38B, etc. within the lane 36, tag fragmentation of the first DNA sample 54 by the first plurality of transposome complexes 38A or 38B, etc. can be performed as described herein.

[0349] In this example method, the transposase 46 of each transposome complex in the first plurality of transposome complexes 38A or 38B, etc. is then removed. Removal of the transposase 46 can be performed using any of the methods described herein (e.g., using sodium dodecyl sulfate (SDS) or a protease or another chaotropic agent, or by heating the flow cell to about 60° C.). The released transposase 46 can be removed from the flow cell 10 using a wash solution.

[0350] Using gap-filling ligation or extension reactions as described herein, a fully adapted DNA fragment 56 can be formed in the first region 76A, and the method used will depend on the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F used.

[0351] All of these processes can be performed with a second fluid (including a second plurality of transposome complexes 38A or 38B, etc., with a second spatial tag 102B) and a second DNA sample 54B to generate fully adapted second DNA sample fragments in a second region 76B. The process can then be repeated again for as many fluids, DNA samples, and regions / areas 76C, 76D, 76E, 76F as needed and / or possible within a given flow cell lane 36. This will allow for multiple DNA samples 54, 54B to be tagged and fragmented in corresponding regions 76A, 76B, etc., which will continue through clustering.

[0352] Since the transposome complexes 38A or 38B, etc. are introduced sequentially and attached only in the regions 76A, 76B, 76C, etc. to which they can hybridize, the transposome complexes 38A or 38B, etc. in a particular fluid may include index sequences in the transferred strand 42 and / or in the adapter 50 introduced into the flow cell 10. This enables standard indexing in addition to spatial indexing.

[0353] Once all fully-matched DNA sample fragments 56 are generated, amplification and cluster generation can be performed as described herein. Cutting of the DNA sample fragments that are fully-matched in the forward or reverse direction can then be performed. Denaturation will release the cut fragments, leaving other (e.g., reverse or forward) single-stranded fully-matched fragments (e.g., 56A, 56B, etc.) attached to the flow cell surface.

[0354] Sequencing can then be performed. In one example, sequencing by synthesis is performed by introducing a sequencing primer followed by an incorporation mixture comprising labeled nucleotides. Each instance of nucleotide incorporation can be detected using optical imaging.

[0355] Another exemplary method includes: i) generating partially adapted first DNA sample fragments in the first region 76A of the flow cell 10 by: introducing a first fluid (including a first plurality of transposome complexes 38A or 38B, etc.) into the flow cell 10 at a hybridization temperature, whereby the first spatial tags 102A are respectively hybridized with the target primers 100A attached to the recesses 26 located at the first region 76A of the flow cell 10; introducing a first DNA sample 54 into the flow cell 10, whereby the first DNA sample 54 is fragmented by the tags of the first plurality of transposome complexes 38A or 38B, etc.; removing the transposase 46 of each transposome complex in the first plurality of transposome complexes 38A or 38B, etc.; and ii) generating partially adapted first DNA sample fragments in the flow cell 10 by: introducing a first fluid (including a first plurality of transposome complexes 38A or 38B, etc.) into the flow cell 10 at a hybridization temperature, whereby the first spatial tags 102A are respectively hybridized with the target primers 100A attached to the recesses 26 located at the first region 76A of the flow cell 10; introducing a first DNA sample 54 into the flow cell 10, whereby the first DNA sample 54 is fragmented by the tags of the first plurality of transposome complexes 38A or 38B, etc.; removing the transposase 46 of each transposome complex in the first plurality of transposome complexes 38A or 38B, etc.; and The method comprises the following steps: generating partially adapted second DNA sample fragments in the second region 76B of the flow cell 10 by: introducing a second fluid into the flow cell 10 at a hybridization temperature, whereby the second spatial tags 102B respectively hybridize with the target primers 100B attached to the recessed portion 26 located at the second region 76B of the flow cell 10; introducing a second DNA sample 54B into the flow cell 10, whereby the second DNA sample 54B is fragmented by tags such as a second plurality of transposome complexes 38A or 38B; and removing the transposase 46 of each transposome complex in the second plurality of transposome complexes 38A or 38B, etc.; and performing a gap-filling connection or an extension reaction on each of the partially adapted first and second DNA sample fragments to form fully adapted first and second DNA sample fragments.

[0356] Another exemplary method involves solution-based binding to generate a binding complex in which DNA is bound to a transposome complex 38A or 38B, etc. The binding complex is Fig.16A and Fig. 16B The bound complex is introduced into the flow cell lane 36 where it will become attached in the desired region 76A or 76B etc. by hybridization of the spatial tag 102 and the complementary target primer 100. The bound complex is then inactivated and additional bound complexes (formed with different DNA samples) are then added.

[0357] Typically, the method includes exposing a first plurality of transposome complexes 38A or 38B, etc. to a first DNA sample 54, whereby the first DNA sample 54 binds to at least some of the first plurality of transposome complexes 38A or 38B, etc. to form first binding complexes; introducing the first binding complexes into a circulation pool 10, whereby the first spatial tags 102A hybridize with the target primers 100A attached to the recesses 26 located at the first region 76A of the circulation pool 10, respectively; passivating the first binding complexes at the first region 76A of the circulation pool 10; exposing a second plurality of transposome complexes 38A or 38B, etc. to a second DNA sample 54B, whereby the second DNA sample 54B binds to at least some of the second plurality of transposome complexes 38A or 38B, etc. to form second binding complexes; and introducing the second binding complexes into the circulation pool 10, whereby the second spatial tags 102B hybridize with the target primers 100B attached to the recesses 26 located at the second region 76B of the circulation pool 10, respectively.

[0358] At the beginning of this exemplary method, a first fluid (including a first plurality of transposome complexes 38A or 38B, etc. having a first spatial marker 102A) is mixed with a first DNA sample 54 outside of the circulation cell 10. A tag fragmentation buffer is not included so that tag fragmentation does not occur prematurely. Therefore, the first DNA sample 54 is bound to the transposome complexes 38A or 38B, etc., but is not fragmented by the tags. This forms a binding complex of the first DNA sample 54 bound to the first plurality of transposome complexes 38A or 38B, etc.

[0359] The bound complex is then introduced into flow cell lane 36 using any suitable technique.

[0360] The temperature of the flow cell lane 36 is at or reaches the hybridization temperature, so that the first spatial tag 102A hybridizes with the complementary target primer 100A located in the first region 76A, respectively. Since the target primers 100B, 100C, 100D, 100E and 100F located in the other regions 76B, 76C, 76D, 76E and 76F are not complementary to the first spatial tag 100A, the binding complex will not bind in these regions 76B, 76C, 76D, 76E and 76F.

[0361] The binding complex can then be passivated by introducing a passivating component (e.g., a hydrophobic polymer or an antifouling agent) into the circulation pool lane 36. The terminal group of the passivating component may include biotin, which can be attached to the avidin / streptavidin 60' of the transposome complex 38A or 38B containing the spatial tag 102. Alternatively, the terminal group of the passivating component may include any functional group that is orthogonal to the dehybridization conditions used to separate the spatial tag 102, that is, a functional group that is unresponsive to the dehybridization conditions. In still another example, the passivating component may have its own passivation tag (similar to the spatial tag 102), which can be attached to a passivated target primer located in a specific area on the surface of the circulation pool. The passivation tag or target primer may have a cleavage site that allows them to be removed at a desired time in the workflow. As an example, the hydrophobic polymer X has an oligomer A, and the region 76A has a complementary oligomer A'. After the transposome complexes 38E, 38F are hybridized via the target primer in region 76A, the hydrophobic polymer X is hybridized via AA' to inactivate region 76A. When the inactivation needs to be removed, oligomer A or A' can be cleaved by chemicals such as vinyl dT or 8oxoG, which is orthogonal to the cleavage site of the primer and / or transposome complex.

[0362] Passivation may involve forming a hydrophobic polymer shell 104 on the first binding complex, such as Fig.16A Passivation may alternatively involve attaching an antifoulant 106 to the first binding complex, such as Fig. 16B shown.

[0363] Examples of suitable hydrophobic polymers that can be used to form the shell 104 include polypropylene glycol, polycaprolactone, poly(lactic-co-glycolic acid) (PLGA), cellulose acetate, ethyl cellulose, polyalkyl (meth)acrylates, or polydimethylsiloxane (PDMS).

[0364] The antifoulant 106 can be a phosphate, a phosphonate, a zwitterionic end group, an amphoteric polymer end group, a carboxylic acid, a poly(ethylene glycol), a perfluorinated end group, a hydroxyl, a sulfonic acid, a positively chargeable end group, an alkoxy end group, or an anionic polymer end group. Examples of zwitterionic end groups are selected from the group consisting of phosphorylcholine, sulfobetaine, and carboxybetaine. An example of an amphoteric polymer end group is a polymer chain containing both carboxylic acid and amine functional groups, such as a copolymer of methacrylic acid and dimethylammoniumethyl methacrylate. Some examples of antifoulants 106 having perfluorinated end groups are selected from the group consisting of (heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane, 3-(heptafluoroisopropoxy)propyltrimethoxysilane, nonafluorohexyltrimethoxysilane, [perfluoro(polyoxypropyleneoxy)]methoxypropyltrimethoxysilane, 1,3-bis(trifluoropropyl)-1,1,3,3-tetramethyldisilazane, and (tridecafluoro-1,1,2,2-tetrahydrooctyl)dimethylchlorosilane. Examples of end groups that may be positively charged include amines and ammonium. Examples of anionic polymer end groups include polyphosphates, polysulfonates, and polycarboxylates (e.g., poly(meth)acrylic acid).

[0365] The antifoulant 106 may include a linker, such as ethylene or another short alkyl chain, poly(meth)acrylate, tetrazine, or azide, having a biotin or other terminal group for attachment to a binding complex (e.g., via avidin / streptavidin 60').

[0366] The second binding complex can be prepared (outside the circulation cell 10) by mixing the second DNA sample 54B and the second fluid (including the second plurality of transposome complexes 38A or 38B, etc. with spatial tags 102B). In this example, the second fluid also does not include a tag fragmentation buffer. In the second fluid, the second DNA sample 54B is bound to the transposome complex 38A or 38B, etc., but is not fragmented by the tag. This forms a binding complex of the second DNA sample 54B bound to the second plurality of transposome complexes 38A or 38B, etc.

[0367] The second binding complex is then introduced into the circulation pool lane 36 (which includes the passivated first binding complex) using any suitable technique. The temperature of the circulation pool lane 36 is at or reaches the hybridization temperature, so that the second spatial label 102B hybridizes with the complementary target primer 100B located in the second region 76B, respectively. Since the target primers 100A, 100C, 100D, 100E and 100F located in other regions 76A, 76C, 76D, 76E and 76F are not complementary to the second spatial label 100B, the binding complex will not bind in these regions 76A, 76C, 76D, 76E and 76F. In addition, the binding complex at region 76A is passivated, so any free DNA sample 54B (for example, at the end) will not bind to the unused transposome complex 38A or 38B, etc. at the first region 76A. Passivation also prevents any free transposome complexes 38A or 38B etc. from the second solution from additionally binding to the first DNA sample 54A.

[0368] The second bound complex can then be passivated by introducing a passivating component (eg, a hydrophobic polymer or an antifouling agent) into the flow cell lane 36 .

[0369] Then, within a given flow cell lane 36, the process of forming the binding complex, introducing the binding complex and attaching it within the desired flow cell region, and inactivating the newly introduced binding complex can be repeated again for as many binding complexes and regions / zones 76C, 76D, 76E, 76F as needed and / or possible. This will allow multiple binding complexes (each of which includes a different DNA) to attach in the corresponding regions 76A, 76B, etc. Once all binding complexes are introduced and bound to regions 76A, 76B, etc., the inactivating component can be removed. When using a biotin-avidin / streptavidin interaction, the inactivating component can be released by introducing any example of the biotin-streptavidin cleavage composition disclosed herein into the flow cell 10. Alternatively, if the inactivating tag or target primer has a cleavage site, a separate cleavage agent can be introduced to cleave and thereby remove the inactivating component from a specific region 76A, 76B, etc.

[0370] Tag fragmentation can be initiated before or after removal of the inactivating components. This can be achieved by introducing any example of tag fragmentation buffer into flow cell lane 36 and ensuring the temperature is 30°C or above. Tag fragmentation can be performed as described herein.

[0371] In this example method, the transposase 46 of each transposome complex 38A or 38B, etc., is then removed. Removal of the transposase 46 may be performed using any of the methods described herein (e.g., using sodium dodecyl sulfate (SDS) or a protease or another chaotropic agent). Heating may be undesirable in order to avoid dehybridization of the spatial tag 102 and the target primer 100. The released transposase 46 may be removed from the flow cell 10 using a wash solution.

[0372] If the passivation component is not removed prior to tag fragmentation, it should be understood that the passivation component should be removed prior to generating the fully adapted DNA fragments 56 and prior to disrupting the bond between the spatial tag 102 and the transposome complex 38E, 38F. The removal used will depend on how the passivation component is attached (e.g., dehybridization, cleavage of the cleavage site, etc.).

[0373] Using gap-filling ligation or extension reactions as described herein, fully adapted DNA fragments 56 can be formed in all regions 76A, 76B, 76C, 76D, 76E, 76F, and the method used will depend on the transposome complex 38A, or 38B, or 38C and 38D, or 38E and 38F used.

[0374] Once all perfectly matched DNA sample fragments 56 are generated, they are exposed to amplification and cluster generation using primers 55, 57. Then cleavage of the forward or reverse perfectly matched DNA sample fragments can be performed, followed by denaturation. These processes can occur simultaneously with amplification.

[0375] Sequencing can then be performed. In one example, sequencing by synthesis is performed by introducing a sequencing primer followed by an incorporation mixture comprising labeled nucleotides. Each instance of nucleotide incorporation can be detected using optical imaging.

[0376] Any of the examples described herein can be adjusted to perform paired-end sequencing simultaneously. In these cases, the amplification domain and primers can be based on primers described in WO 2020 / 005503, which is incorporated herein by reference in its entirety.

[0377] Additional Notes

[0378] 9A to 13D Each of the examples shows the flow through the flow cell from left to right. Various examples depict the activated region downstream of the non-activated region. However, it should be understood that the activated region can be upstream of the non-activated region, or downstream of one or more non-activated regions and upstream of one or more other non-activated regions.

[0379] It should be understood that all combinations of the foregoing concepts and additional concepts discussed in more detail below (assuming such concepts are not mutually inconsistent) are contemplated as being part of the inventive subject matter disclosed herein. Specifically, all combinations of the claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein. It should also be understood that terms explicitly adopted herein that may also appear in any disclosure incorporated by reference should be given the meaning most consistent with the specific concepts disclosed herein.

[0380] The references to "one example", "another example", "an example", etc. throughout this specification mean that the specific elements (e.g., features, structures, and / or characteristics) described in conjunction with the example are included in at least one example described herein, and may or may not be present in other examples. In addition, it should be understood that the elements used in any example may be combined in various examples in any suitable manner, unless the context clearly indicates otherwise.

[0381] While several examples have been described in detail, it is to be understood that modifications may be made to the disclosed examples. Therefore, the above description should be considered non-limiting.

Claims

1. A circulation cell, comprising: a substrate having recessed portions separated by gap regions; a polymer hydrogel positioned within each of the recessed portions; as well as A plurality of transposome complexes are immobilized in each of the recesses via a biotin-containing linker, each of the plurality of transposome complexes being of a single type and comprising a transposon end, wherein a portion of a transferred strand is hybridized to a portion of a non-transferred strand, wherein the transferred strand comprises a first amplification domain and does not contain an index sequence. 2 . The flow cell according to claim 1 , wherein the non-transferred strand consists of the portion hybridized with the portion of the transferred strand.

3. The flow cell of claim 1 or claim 2, further comprising a first primer and a second primer immobilized in each of the recesses via a corresponding second biotin-containing linker, and wherein: The first primer corresponds to the first amplification domain; and The second primer has a sequence complementary to a second amplification domain of an adaptor to which a portion of the transferred strand is to be hybridized.

4. The flow cell according to claim 1, wherein: The transferred strand and the non-transferred strand form a forked adaptor; and The non-transferred strand further comprises a sequencing primer sequence, an index sequence, and a second amplification domain complementary to a primer to be immobilized within each of the recesses of the flow cell.

5. The flow cell of claim 1, further comprising a first primer and a second primer immobilized in each of the recesses via a corresponding second biotin-containing linker, wherein: The first primer corresponds to the first amplification domain; The transferred strand and the non-transferred strand form a forked adaptor; and The non-transferred strand also includes a sequencing primer sequence, an index sequence, and a second amplification domain complementary to the second primer.

6. A tag fragmentation kit, comprising: A circulation cell, comprising: a substrate having recessed portions separated by gap regions; and a plurality of transposome complexes immobilized in each of the recesses via a biotin-containing linker, each of the plurality of transposome complexes being of a single type and comprising a transposon end, wherein a portion of a transferred strand is hybridized to a non-transferred strand, wherein the transferred strand comprises a first amplification domain; and An adaptor fluid, the adaptor fluid comprising: a carrier fluid; and An adaptor, the adaptor comprising: a sequence complementary to the portion of the transferred strand of each transposome complex in the plurality of transposome complexes; Sequencing primer sequences; Index sequence; and A second amplification domain complementary to a primer to be immobilized within each of the recesses of the flow cell.

7. The tag fragmentation kit according to claim 6, further comprising a grafting fluid, wherein the grafting fluid comprises: a second carrier fluid; First primer; as well as A second primer complementary to the second amplification domain, each of the first primer and the second primer having a second biotin-containing linker at its 5' end.

8. The tag fragmentation kit according to claim 6, wherein the flow cell further comprises: First primer; as well as A second primer complementary to the second amplification domain, each of the first primer and the second primer is immobilized within each of the recesses via a second biotin-containing linker at its 5' end.

9. A tag fragmentation kit, comprising: A circulation cell, comprising: a substrate having recessed portions separated by gap regions; and a plurality of transposome complexes immobilized in each of the recesses via a biotin-containing linker, each of the plurality of transposome complexes being of a single type and comprising a transposon end, wherein a portion of a transferred strand hybridizes with a portion of a non-transferred strand to form a forked adaptor, wherein the transferred strand comprises a first amplification domain, a sequencing primer sequence, an index sequence, and a second amplification domain complementary to a primer to be immobilized in each of the recesses of the flow cell; and A grafted fluid, the grafted fluid comprising: Carrier fluid; a first primer; and A second primer complementary to the second amplification domain, each of the first primer and the second primer having a second biotin-containing linker at its 5' end.

10. A method comprising: generating at least partially adapted DNA sample fragments on a flow cell using a plurality of transposome complexes attached to a surface of the flow cell within a flow channel via a biotin-containing linker; cleaving the at least partially adapted DNA sample fragment such that the biotin-containing linker remains attached to the surface; as well as One of the following: Using the flow cell to perform subsequent cycles of generating at least partially adapted DNA sample fragments; or At least some of the previously cleaved and at least partially adapted DNA sample fragments are amplified using the flow cell.

11. The method according to claim 10, wherein: Each transposome complex of the plurality of transposome complexes is of a single type, comprising a transposon end, wherein a portion of a transferred strand hybridizes with a portion of a non-transferred strand to form a forked adaptor, wherein the transferred strand comprises a first amplification domain, and wherein the non-transferred strand further comprises a sequencing primer sequence, an index sequence, and a second amplification domain, The second amplification domain is complementary to a primer immobilized or to be immobilized in each of the recesses of the flow cell; Each of the at least partially adapted DNA sample fragments is a fully adapted DNA sample fragment; and Generating the fully adapted DNA sample fragments comprises: introducing a DNA sample and a tag fragmentation buffer into the flow cell; Using the plurality of transposome complexes to perform tag fragmentation of the DNA sample; removing the transposase from each of the plurality of transposome complexes; and Gap-fill ligation was performed to attach the DNA sample fragments to the corresponding adaptors.

12. The method of claim 11, wherein after cleaving the fully adapted DNA sample fragments such that the biotin-containing adapter remains attached to the surface, and before using the flow cell, the method further comprises removing streptavidin from the biotin-containing adapter.

13. The method according to any one of claims 10 to 12, wherein the flow cell is used for the subsequent cycles of generating at least partially adapted DNA sample fragments, and wherein the subsequent cycles of generating at least partially adapted DNA sample fragments involve: introducing a new plurality of transposome complexes into the flow channel, whereby at least some of the new plurality of transposome complexes are attached to at least some of the biotin-containing linkers within the flow channel; introducing a new DNA sample and a new tag fragmentation buffer into the flow channel; and The tag fragmentation, transposase removal and gap-filling ligation were repeated with the new DNA sample.

14. The method of claim 11 or claim 12, wherein the flow cell is used for amplification of the previously cleaved and perfectly adapted DNA sample fragments, and wherein the amplification of the previously cleaved and perfectly adapted DNA sample fragments involves: attaching a first primer and a second primer to at least some of the biotin-containing linkers within the flow channel; and The previously cleaved and fully adapted DNA sample fragments are introduced into the flow cell in single-stranded form.

15. The method of claim 10, wherein: Each transposome complex in the plurality of transposome complexes is of a single type and includes a transposon end in which a portion of a transferred strand is hybridized to a non-transferred strand; The transferred strand includes a first amplification domain; Each of the at least partially adapted DNA sample fragments is a fully adapted DNA sample fragment; and Generating the fully adapted DNA sample fragments comprises: introducing a DNA sample and a tag fragmentation buffer into the flow channel; Using the plurality of transposome complexes to perform tag fragmentation of the DNA sample; removing the transposase from each of the plurality of transposome complexes; and The non-transferred strand of each transposome complex in the plurality of transposome complexes is replaced with an adaptor, the adaptor comprising: a sequence complementary to said portion of said transferred strand; Sequencing primer sequences; Index sequence; and a second amplification domain complementary to a primer immobilized or to be immobilized in each of the recesses of the flow cell, thereby dehybridizing the non-transferred strand and hybridizing the adaptor to the portion of the transferred strand of each of the plurality of transposome complexes; and Gap-fill ligation was performed to attach the DNA sample fragments to the corresponding adaptors.

16. The method of claim 15, wherein after cleaving the fully adapted DNA sample fragments such that the biotin-containing linker remains attached to the surface, and before using the flow cell, the method further comprises removing streptavidin from the biotin-containing linker.

17. The method of claim 15 or claim 16, wherein the flow cell is used for the subsequent cycles of generating at least partially adapted DNA sample fragments, and wherein the subsequent cycles of generating fully adapted DNA sample fragments comprise: introducing a new plurality of transposome complexes into the flow channel, whereby at least some of the new plurality of transposome complexes are attached to at least some of the biotin-containing linkers within the flow channel; introducing a new DNA sample and a new tag fragmentation buffer into the flow channel; as well as The tag fragmentation, transposase removal, replacement of the non-transferred strand with the adaptor and gap-filling ligation with the new DNA sample are repeated.

18. The method of claim 15 or claim 16, wherein the flow cell is used for amplification of the previously cleaved and perfectly adapted DNA sample fragments, and wherein the amplification of the previously cleaved and perfectly adapted DNA sample fragments involves: attaching a first primer and a second primer to at least some of the biotin-containing linkers within the flow channel; and The previously cleaved and fully adapted DNA sample fragments are introduced into the flow cell in single-stranded form.

19. The method of claim 10, wherein: The plurality of transposome complexes include a first transposome complex comprising a first amplification domain and a second transposome complex comprising a second amplification domain; Each of the at least partially adapted DNA sample fragments is a fully adapted DNA sample fragment; and Generating the fully adapted DNA sample fragments comprises: introducing a DNA sample and a tag fragmentation buffer into the flow cell; Using the plurality of transposome complexes to perform tag fragmentation of the DNA sample; removing the transposase from each of the plurality of transposome complexes; and Perform the extension reaction.

20. The method of claim 19, wherein some of the fully-matched DNA sample fragments include a targeted region, and wherein after cleaving the fully-matched DNA sample fragments, the method further comprises generating an enriched sample by: Denaturing the fully-matched DNA sample fragments to generate single-stranded fully-matched DNA sample fragments, wherein some of the single-stranded fully-matched DNA sample fragments include the targeted region; transporting the single-stranded fully adapted DNA sample fragments to an enrichment container on the flow cell; and A biotinylated capture probe is introduced into the enrichment container, whereby some fragments of the single-stranded fully adapted DNA sample fragments having the targeted region are hybridized with the biotinylated capture probe to form enriched complexes, respectively, and some other fragments of the single-stranded fully adapted DNA sample fragments not having the targeted region remain unattached.

21. The method according to claim 20, further comprising: supplementing the flow channel with streptavidin; transporting the enriched sample to the flow channel comprising supplemented streptavidin, whereby the enriched complexes are attached to the biotin-containing linker and the single-stranded fully adapted DNA sample fragments without the targeting region remain unattached; introducing a washing solution into the flow channel to remove the single-stranded fully adapted DNA sample fragments that do not have the targeting region; releasing the fragments having the targeted region from the biotinylated capture probes; and The fragments having the targeted region among the single-stranded fully adapted DNA sample fragments are transported to a holding container.

22. The method according to claim 21, wherein when the some of the single-stranded fully adapted DNA sample fragments having the targeted region are in the holding container, the method further comprises removing streptavidin from the biotin-containing adapter in the flow channel; and A first primer and a second primer are attached to at least some of the biotin-containing linkers within the flow channel.

23. A method according to claim 21 or claim 22, wherein the circulation pool is used for amplification of the previously cut and fully adapted DNA sample fragments, and wherein the amplification of the previously cut and fully adapted DNA sample fragments is initiated by transporting some of the fragments of the single-stranded fully adapted DNA sample fragments having the targeted region from the retaining container to the flow channel after the first primer and the second primer have been attached.

24. The method of claim 10, wherein: Each transposome complex in the plurality of transposome complexes is of a single type and includes a transposon end in which a portion of a transferred strand is hybridized to a non-transferred strand; The transferred strand includes a first amplification domain; Each of the at least partially adapted DNA sample fragments is a partially adapted DNA sample fragment; Generating the partially adapted DNA sample fragments comprises: introducing a DNA sample and a tag fragmentation buffer into the flow channel; Using the plurality of transposome complexes to perform tag fragmentation of the DNA sample; and The transposase is removed from each of the plurality of transposome complexes.

25. The method according to claim 24, wherein after the partially adapted DNA sample fragments are cut, the method further comprises: Denaturing the partially adapted DNA sample fragments to generate single-stranded partially adapted DNA sample fragments, wherein some of the single-stranded partially adapted DNA sample fragments include the targeted region; transporting the DNA sample fragments adapted to the single-stranded portion to an enrichment container on the flow pool, the enrichment container comprising a surface-bound adaptor having a second amplification domain and a region complementary to the targeting region, whereby some of the DNA sample fragments adapted to the single-stranded portion having the targeting region are hybridized with the surface-bound adaptor, respectively, and some other of the DNA sample fragments adapted to the single-stranded portion not having the targeting region remain unattached; introducing a washing solution into the enrichment container to remove DNA sample fragments that are not compatible with the single-stranded portion of the targeting region; as well as Extension reactions are performed along the surface-bound adaptors to generate fully-matched DNA sample fragments.

26. A method comprising: capturing a plurality of biotinylated dDpn1 at a plurality of biotin-containing linkers attached to a surface within a flow channel of a flow cell; introducing a DNA sample into the flow cell, whereby the methylated bacterial DNA in the DNA sample is captured by the biotinylated dDpn1; introducing a wash solution into the flow channel to remove uncaptured DNA sample therefrom; releasing the methylated bacterial DNA from the biotinylated dDpn1 such that the biotin-containing linker remains attached to the surface; transporting the cleaved methylated bacterial DNA to a holding vessel; While the cleaved methylated bacterial DNA is in the holding container: supplementing streptavidin from the biotin-containing linker; introducing a plurality of biotinylated transposome complexes into the flow channel, whereby the plurality of biotinylated transposome complexes are attached to some of the biotin-containing linkers; as well as introducing a plurality of biotinylated primers into the flow channel, whereby the plurality of biotinylated primers are attached to others of the biotin-containing linkers; as well as The cleaved methylated bacterial DNA is transported back to the flow channel containing the biotinylated transposome complex and the biotinylated primer.

27. A method comprising: introducing the tagged fragmentation entity having a first visible light responsive member attached thereto into a flow cell having a second visible light responsive member attached thereto; as well as When the tag fragmentation entity is present in the flow cell, a predetermined area of ​​the flow cell is exposed to visible light, thereby coupling the first and second visible light responsive members and attaching the tag fragmentation entity to the flow cell at the predetermined area.

28. The method according to claim 27, further comprising: introducing a primer having the first visible light responsive member attached thereto into the flow cell; as well as When the primer is present in the flow cell, a second predetermined area of ​​the flow cell is exposed to visible light, thereby coupling the first and second visible light responsive members and attaching the primer to the flow cell at the second predetermined area.

29. According to claim 27 or claim 28 The method, wherein after the tag fragmentation entity is coupled, the method further comprises: introducing a DNA sample into the flow cell; Initiating tag fragmentation of the DNA sample using a coupled tag fragmentation entity; a transposase that removes the tag fragmented entity; as well as A second tag fragmentation entity having the first visible light responsive member attached thereto is coupled at a second predetermined area of ​​the flow cell by: introducing the second tag fragmentation entity into the flow cell; as well as When the second tag fragmentation entity is present in the flow cell, the second predetermined area of ​​the flow cell is exposed to visible light, thereby coupling the first and second visible light responsive members and attaching the second tag fragmentation entity to the flow cell at the second predetermined area.

30. The method of claim 29, wherein the first tag fragmentation entity and the second tag fragmentation entity have different index sequences.

31. A kit, comprising: A circulation cell, comprising: a substrate having recessed portions separated by gap regions; and a biotinylated polymer hydrogel positioned within each of the recessed portions; A transpososome fluid, the transpososome fluid comprising: a first carrier fluid; and Multiple biotinylated transposome complexes; A grafted fluid, the grafted fluid comprising: a second carrier fluid; and a plurality of biotinylated amplification primers; and Streptavidin.

32. The kit of claim 31, further comprising a biotinylated enrichment probe.

33. The kit of claim 31 or claim 32, further comprising a biotin-streptavidin cleavage composition.

34. The kit according to any one of claims 31 to 33, further comprising a cleavage agent that cleaves the cleavage site of each biotinylated transposome complex.

35. A kit according to any one of claims 31 to 34, wherein: Each biotinylated transposome complex is of a single type and includes a transposon end wherein a portion of a transferred strand is hybridized to a non-transferred strand, wherein the transferred strand includes a first amplification domain; and The kit further comprises an adaptor fluid, the adaptor fluid comprising: a third carrier fluid; and An adaptor, the adaptor comprising: a sequence complementary to the portion of the transferred strand of each transposome complex in the plurality of transposome complexes; Sequencing primer sequences; Index sequence; and A second amplification domain is complementary to one type of the plurality of biotinylated amplification primers.

36. The kit of any one of claims 31 to 34, wherein the plurality of biotinylated transposome complexes comprises: a first transposome complex comprising a first amplification domain having a sequence identical to one type of the plurality of biotinylated amplification primers; as well as A second transposome complex comprising a second amplification domain having a sequence identical to a second type of the plurality of biotinylated amplification primers.

37. A kit according to any one of claims 31 to 34, wherein: The plurality of biotinylated transposome complexes includes a first transposome complex including a first amplification domain having a sequence identical to one type of the plurality of biotinylated amplification primers; and The flow cell also includes an enrichment chamber comprising a surface-bound adaptor having a second amplification domain and a region complementary to a target sample region, the second amplification domain having a sequence identical to a second type of the plurality of biotinylated amplification primers.

38. A method comprising: selectively activating a subset of transposome complexes in a predetermined region of a flow cell by heating the predetermined region to an activation temperature and cooling another region of the flow cell to below the activation temperature, wherein the flow cell comprises: a substrate having recessed portions separated by gap regions; a polymer hydrogel positioned within each of the recessed portions; and the transposome complex respectively fixed in each of the recessed portions; and A DNA sample is introduced into the flow cell, whereby a portion of the DNA sample binds to a subset of the transposome complexes in the predetermined region and is fragmented by their tags, and another portion of the DNA sample binds to the transposome complexes in the other region but remains unfragmented by their tags.

39. The method of claim 38, wherein the activation temperature is in the range of about 20°C to about 55°C.

40. The method of claim 38 or claim 39, further comprising: removing the transposase from each of the transposome complexes, thereby releasing the other portion of the DNA sample, and whereby the portion of the DNA sample remains attached to the predetermined region; washing the transposase and released DNA sample removed from the flow cell; as well as Fresh transposase is introduced into the flow cell, thereby reforming the transposome complex in the other region.

41. A method according to any one of claims 38 to 40, wherein: The second predetermined area of ​​the circulation pool corresponds to at least a portion of the other area; and The method further comprises: selectively activating a second subset of transposome complexes in the second predetermined region by heating the second predetermined region to the activation temperature and cooling at least the predetermined region of the flow cell to below the activation temperature; as well as A second DNA sample is introduced into the flow cell, whereby a portion of the second DNA sample binds to a second subset of the transposome complexes in the second predetermined region and is fragmented by tags thereof.

42. A method comprising: The DNA sample is introduced into a flow cell comprising: a substrate having recessed portions separated by gap regions; a polymer hydrogel positioned within each of the recessed portions; and a transposome complex secured within each of the recesses; Whereby the DNA sample is bound to the transposome complex across the flow cell; introducing an encapsulated composite into the flow cell, the encapsulated composite comprising a catalytic metal surrounded by a coating material; and The catalytic metal is selectively released from the encapsulated complex at a predetermined area of ​​the circulation pool by exposing the encapsulated complex to a mechanism that initiates removal of the coating material, thereby initiating tag fragmentation of a portion of the DNA sample in the predetermined area, while leaving another portion of the DNA sample unfragmented by the tag in another area.

43. The method of claim 42, wherein the mechanism is heat and the method further comprises cooling the other region of the flow cell to prevent catalytic metal release from occurring in the other region.

44. The method of claim 42, wherein the mechanism is light.

45. The method of claim 42, wherein the mechanism is a pH change.

46. ​​The method according to any one of claims 42 to 45, further comprising: removing the transposase of each of the transposome complexes, thereby releasing the further portion of the DNA sample from the further region, and whereby the portion of the DNA sample remains attached to the predetermined region; washing the transposase removed from the flow cell and another portion of the released DNA sample; as well as Fresh transposase is introduced into the flow cell, thereby reforming the transposome complex in the other region.

47. The method of claim 46, wherein: The second predetermined area of ​​the circulation pool corresponds to at least a portion of the other area; and The method further comprises: introducing a second DNA sample into the flow cell, whereby the second DNA sample binds to the transposome complex across the flow cell; introducing a second encapsulated composite into the flow cell, the second encapsulated composite comprising a second catalytic metal surrounded by a second coating material; and The second catalytic metal is selectively released from the second encapsulated complex at the second predetermined region by exposing the second encapsulated complex to a second mechanism that initiates removal of the second coating material, thereby initiating tag fragmentation of a portion of the second DNA sample in the second predetermined region.

48. A method comprising: The DNA sample is introduced into a flow cell comprising: a substrate having recessed portions separated by gap regions; a polymer hydrogel positioned within each of the recessed portions; a transposome complex immobilized within each of the recesses; and a removable coating covering the transposome complex; exposing a subset of the transposome complexes at a predetermined area of ​​the flow cell by removing a portion of the removable coating from the predetermined area; and Tag fragmentation of at least a portion of the DNA sample is initiated at the predetermined region.

49. The method of claim 48, wherein exposing the subset of the transposome complexes involves heating the predetermined region, and the method further comprises cooling another region of the flow cell to prevent removal of another portion of the removable coating from the another region.

50. The method of claim 48, wherein exposing the subset of the transposome complexes involves exposing the predetermined region to visible light.

51. The method of claim 48, wherein exposing the subset of the transposome complexes involves changing the pH at the predetermined region.

52. The method according to any one of claims 48 to 51, further comprising: removing a transposase from said transposome complexes in said subset; as well as The transposase is removed from the flow cell by washing.

53. The method of claim 52, wherein: The second predetermined area of ​​the circulation pool corresponds to at least a portion of the other area; and The method further comprises: introducing a second DNA sample into the flow cell; exposing a second subset of the transposome complexes at the second predetermined area of ​​the flow cell by removing a second portion of the removable coating from the second predetermined area; and Tag fragmentation of at least a portion of the second DNA sample is initiated at the second predetermined region.

54. A kit, comprising: A circulation cell, the circulation cell comprising: a substrate having recessed portions separated by gap regions; a polymer hydrogel positioned within each of the recessed portions; a set of amplification primers attached to the polymer hydrogel within each of the recesses; and a target primer attached to the polymer hydrogel within each of the recesses, wherein the target primer attached within the recess located at the first region of the flow cell is orthogonal to the target primer attached within the recess located at the second region of the flow cell; A first fluid, the first fluid comprising: a liquid carrier; and a first plurality of transposome complexes dispersed in the liquid carrier, each of the first plurality of transposome complexes comprising a first spatial tag complementary to the target primer attached within the recess located at the first region of the flow cell; and A second fluid, wherein the second fluid comprises: a liquid carrier; and A second plurality of transposome complexes are dispersed in the liquid carrier, each of the second plurality of transposome complexes comprising a second spatial tag complementary to the target primer attached within the recess located at the second region of the flow cell.

55. The kit of claim 54, wherein: Each first spatial tag is attached to the 5′ end of the transferred strand of each transposome complex in the first plurality of transposome complexes; and Each second spatial tag is attached to the 5' end of the transferred strand of each transposome complex in the second plurality of transposome complexes.

56. The kit of claim 54, wherein: Some of the first spatial tags are respectively attached to the 5′ ends of the transferred strands of some of the transposome complexes in the first plurality of transposome complexes; Some other of the first spatial tags are respectively attached to the 3′ end of the non-transferred strand of some other transposome complexes in the first plurality of transposome complexes; Some of the second spatial tags are respectively attached to the 5′ end of the transferred strands of some of the transposome complexes in the second plurality of transposome complexes; and Some other of the second spatial tags are respectively attached to the 3′ end of the non-transferred strand of some other of the second plurality of transposome complexes.

57. A method for using the kit according to claim 54, the method comprising: operatively positioning the flow cell in a sequencing instrument; The fully adapted first DNA sample fragments are generated in the first region of the flow cell by: introducing the first fluid into the flow cell at a hybridization temperature, whereby the first spatial tags are respectively hybridized with the target primers attached to the recessed portions located at the first region of the flow cell; introducing a first DNA sample into the flow cell, whereby the first DNA sample is fragmented by the first plurality of transposome complex tags; removing the transposase from each transposome complex in the first plurality of transposome complexes; as well as performing a gap-filling ligation or extension reaction; and The fully matched second DNA sample fragments are generated in the second region of the flow cell by: introducing the second fluid into the flow cell at a hybridization temperature, whereby the second spatial tags are respectively hybridized with the target primers attached to the recessed portions located at the second region of the flow cell; introducing a second DNA sample into the flow cell, whereby the second DNA sample is fragmented by the second plurality of transposome complex tags; removing the transposase from each transposome complex in the second plurality of transposome complexes; as well as Perform a gap-filling ligation or extension reaction.

58. A method for using the kit according to claim 54, the method comprising: operatively positioning the flow cell in a sequencing instrument; exposing the first plurality of transposome complexes to a first DNA sample, whereby the first DNA sample binds to at least some of the first plurality of transposome complexes to form first bound complexes; introducing the first binding complex into the flow cell, whereby the first spatial tags are respectively hybridized with the target primers attached to the recessed portions located at the first region of the flow cell; passivating the first bound complex at the first region of the flow cell; exposing the second plurality of transposome complexes to a second DNA sample, whereby the second DNA sample binds to at least some of the second plurality of transposome complexes to form second bound complexes; as well as The second binding complex is introduced into the flow cell, whereby the second spatial tags are respectively hybridized with the target primers attached within the recesses located at the second region of the flow cell.

59. The method of claim 58, further comprising passivating the second bound complex at the second region of the flow cell.

60. The method of claim 58 or claim 59, wherein passivating the first binding complex involves attaching an antifouling agent to the first binding complex.

61. The method of claim 58 or claim 59, wherein passivating the first binding complex involves forming a hydrophobic polymer shell on the first binding complex.

62. The method of any one of claims 58 to 61, further comprising: depassivating the first bound complex at the first region of the flow cell; as well as The formation of a corresponding set of fully adapted DNA fragments is initiated simultaneously in each of the first and second regions of the flow cell.

63. A method for using the kit according to claim 54, the method comprising: operatively positioning the flow cell in a sequencing instrument; Partially adapted first DNA sample fragments are generated in the first region of the flow cell by: introducing the first fluid into the flow cell at a hybridization temperature, whereby the first spatial tags are respectively hybridized with the target primers attached to the recessed portions located at the first region of the flow cell; introducing a first DNA sample into the flow cell, whereby the first DNA sample is fragmented by the first plurality of transposome complex tags; as well as removing the transposase from each transposome complex in the first plurality of transposome complexes; Partially adapted second DNA sample fragments are generated in the second region of the flow cell by: introducing the second fluid into the flow cell at a hybridization temperature, whereby the second spatial tags are respectively hybridized with the target primers attached to the recessed portions located at the second region of the flow cell; introducing a second DNA sample into the flow cell, whereby the second DNA sample is fragmented by the second plurality of transposome complex tags; as well as removing the transposase from each transposome complex in the second plurality of transposome complexes; as well as A gap-filling ligation or extension reaction is performed to generate fully matched first DNA sample fragments and second DNA sample fragments.

64. A method comprising: attaching sets of amplification primers along the flow cell lanes; as well as Orthogonal target primers are sequentially attached in at least two different regions of the flow cell lane.

Citation Information

Cited By

  • Genomic analysis using tagmentation

    WO2026136388A1